ClearPoint Neuro (CLPT) 10-K 26 Feb 25 2024 FY Annual report Financial data

Cover

Cover - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Feb. 18, 2025	Jun. 30, 2024
Cover [Abstract]
Document Type	10-K
Document Annual Report	true
Document Period End Date	Dec. 31, 2024
Current Fiscal Year End Date	--12-31
Document Transition Report	false
Entity File Number	001-34822
Entity Registrant Name	CLEARPOINT NEURO, INC.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	58-2394628
Entity Address, Address Line One	120 S. Sierra Ave.
Entity Address, Address Line Two	Suite 100
Entity Address, City or Town	Solana Beach
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92075
City Area Code	888
Local Phone Number	287-9109
Title of 12(b) Security	Common Stock, $0.01 par value per share
Trading Symbol	CLPT
Security Exchange Name	NASDAQ
Entity Well-known Seasoned Issuer	No
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
ICFR Auditor Attestation Flag	false
Document Financial Statement Error Correction [Flag]	false
Entity Shell Company	false
Entity Public Float			$ 145
Entity Common Stock, Shares Outstanding		27,632,332
Documents Incorporated by Reference	The information required by Part III is incorporated by reference from portions of the definitive proxy statement to be filed within 120 days after December 31, 2024 , pursuant to Regulation 14A under the Securities Exchange Act of 1934 in connection with the 2025 annual meeting of stockholders.
Amendment Flag	false
Document Fiscal Period Focus	FY
Document Fiscal Year Focus	2024
Entity Central Index Key	0001285550
Auditor Opinion	Opinion on the Financial Statements We have audited the accompanying consolidated balance sheets of ClearPoint Neuro, Inc. (the “Company”) as of December 31, 2024 and 2023, and the related consolidated statements of operations, stockholders’ equity, and cash flows for the years then ended, and the related notes to the consolidated financial statements. In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2024 and 2023, and the results of its operations and its cash flows for the years then ended, in conformity with accounting principles generally accepted in the United States of America.
Auditor Firm ID	677
Auditor Name	Cherry Bekaert LLP
Auditor Location	Tampa, Florida

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Current assets:
Cash and cash equivalents	$ 20,104	$ 23,140
Accounts receivable, net	4,713	3,211
Inventory, net	6,863	7,911
Prepaid expenses and other current assets	1,683	1,910
Total current assets	33,363	36,172
Property and equipment, net	2,005	1,389
Operating lease rights of use	3,086	3,564
Software license inventory	103	386
Licensing rights	484	1,041
Other assets	148	109
Total assets	39,189	42,661
Current liabilities:
Accounts payable	1,340	393
Accrued compensation	4,885	2,947
Other accrued liabilities	1,450	1,053
Operating lease liabilities, current portion	557	424
Deferred product and service revenue, current portion	2,121	2,613
Total current liabilities	10,353	7,430
Operating lease liabilities, net of current portion	3,011	3,568
Deferred product and service revenue, net of current portion	436	541
2020 senior secured convertible note payable, net	0	9,949
Total liabilities	13,800	21,488
Commitments and contingencies (Note 8)
Stockholders' equity:
Preferred stock, $0.01 par value; 25,000,000 shares authorized at December 31, 2024 and 2023; none issued and outstanding at December 31, 2024 and 2023	0	0
Common stock, $0.01 par value; 90,000,000 shares authorized at December 31, 2024 and 2023; 27,617,415 and 24,652,729 shares issued and outstanding at December 31, 2024 and 2023, respectively	276	247
Additional paid-in capital	216,483	193,382
Accumulated deficit	(191,370)	(172,456)
Total stockholders’ equity	25,389	21,173
Total liabilities and stockholders’ equity	$ 39,189	$ 42,661

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - $ / shares	Dec. 31, 2024	Dec. 31, 2023
Statement of Financial Position [Abstract]
Preferred stock par value (in dollars per share)	$ 0.01	$ 0.01
Preferred stock, shares authorized (in shares)	25,000,000	25,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock par value (in dollars per share)	$ 0.01	$ 0.01
Common stock, shares authorized (in shares)	90,000,000	90,000,000
Common stock, shares issued (in shares)	27,617,415	24,652,729
Common stock, shares outstanding (in shares)	27,617,415	24,652,729

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Revenue:
Total revenue	$ 31,390	$ 23,955
Cost of revenue	12,268	10,341
Gross profit	19,122	13,614
Research and development costs	12,392	11,709
Sales and marketing expenses	14,478	12,595
General and administrative expenses	11,998	11,756
Operating loss	(19,746)	(22,446)
Other income (expense):
Other expense, net	(40)	(29)
Interest income, net	872	386
Net loss	$ (18,914)	$ (22,089)
Net loss per share attributable to common stockholders:
Basic (in dollars per share)	$ (0.7)	$ (0.9)
Diluted (in dollars per share)	$ (0.7)	$ (0.9)
Weighted average shares outstanding:
Basic (in shares)	27,027,692	24,605,212
Diluted (in shares)	27,027,692	24,605,212
Product revenue
Revenue:
Total revenue	$ 18,626	$ 10,603
Service and other revenue
Revenue:
Total revenue	$ 12,764	$ 13,352

Consolidated Statements of Stoc

Consolidated Statements of Stockholders' Equity - USD ($) $ in Thousands	Total	Common Stock	Additional Paid-in Capital	Accumulated Deficit
Balances at beginning (in shares) at Dec. 31, 2022		24,578,983
Balances at beginning at Dec. 31, 2022	$ 36,887	$ 246	$ 187,008	$ (150,367)
Issuances of common stock:
Share-based compensation (in shares)		9,538
Share-based compensation	6,079		6,079
Option exercises (cashless) (in shares)		14,312
Issuance of common stock under employee stock purchase plan (in shares)		84,430
Issuance of common stock under employee stock purchase plan	506	$ 1	505
Payments for taxes related to net share settlement of equity awards (in shares)		(34,534)
Payments for taxes related to net share settlement of equity awards	(210)		(210)
Net loss for the year	$ (22,089)			(22,089)
Balance at ending (in shares) at Dec. 31, 2023	24,652,729	24,652,729
Balances at ending at Dec. 31, 2023	$ 21,173	$ 247	193,382	(172,456)
Issuances of common stock:
Public offering of common stock, net of offering costs (in shares)		2,653,848
Public offering of common stock, net of offering costs	16,183	$ 26	16,157
Share-based compensation (in shares)		260,552
Share-based compensation	6,907	$ 2	6,905
Option exercises (cash and cashless) (in shares)		12,258
Option exercises (cash and cashless)	21		21
Issuance of common stock under employee stock purchase plan (in shares)		97,093
Issuance of common stock under employee stock purchase plan	443	$ 1	442
Payments for taxes related to net share settlement of equity awards (in shares)		(59,065)
Payments for taxes related to net share settlement of equity awards	(424)		(424)
Net loss for the year	$ (18,914)			(18,914)
Balance at ending (in shares) at Dec. 31, 2024	27,617,415	27,617,415
Balances at ending at Dec. 31, 2024	$ 25,389	$ 276	$ 216,483	$ (191,370)

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Cash flows from operating activities:
Net Income (Loss)	$ (18,914)	$ (22,089)
Adjustments to reconcile net loss to net cash flows from operating activities:
Allowance for credit losses (recoveries)	(296)	1,258
Depreciation and amortization	980	626
Share-based compensation	6,907	6,079
Amortization of debt issuance costs and original issue discounts	51	57
Amortization of lease right of use assets, net of accretion in lease liabilities	923	831
Accretion of discounts on short-term investments	0	(126)
Increase (decrease) in cash resulting from changes in:
Accounts receivable	(1,206)	(1,804)
Inventory, net	743	1,246
Prepaid expenses and other current assets	262	(113)
Other assets	(39)	22
Accounts payable and accrued expenses	3,105	(649)
Lease liabilities	(869)	(755)
Deferred revenue	(597)	1,697
Net cash flows from operating activities	(8,950)	(13,720)
Cash flows from investing activities:
Purchases of property and equipment	(275)	(717)
Acquisition of licensing rights	0	(334)
Proceeds from maturities of short-term investments	0	10,000
Net cash flows from investing activities	(275)	8,949
Cash flows from financing activities:
Proceeds from public offering of common stock, net of offering costs	16,149	0
Repayment of 2020 senior secured convertible note	(10,000)	0
Proceeds from stock option exercises	21	0
Proceeds from issuance of common stock under employee stock purchase plan	443	506
Payments for taxes related to net share settlement of equity awards	(424)	(210)
Net cash flows from financing activities	6,189	296
Net change in cash and cash equivalents	(3,036)	(4,475)
Cash and cash equivalents, beginning of year	23,140	27,615
Cash and cash equivalents, end of year	20,104	23,140
Cash paid for:
Income taxes	62	0
Interest	$ 480	$ 743

Consolidated Statements of Ca_2

Consolidated Statements of Cash Flows (Parenthetical) - USD ($) $ in Millions	1 Months Ended	12 Months Ended
	Jun. 30, 2023	Dec. 31, 2024	Dec. 31, 2023
Statement of Cash Flows [Abstract]
Capital expenditures accrued, not yet paid		$ 0.2
Net transfers of reusable components from loaned systems		$ 0.4	$ 0.1
Right-of-use assets obtained in exchange for operating lease liability	$ 2.5

Pay vs Performance Disclosure

Pay vs Performance Disclosure - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Pay vs Performance Disclosure
Net Income (Loss)	$ (18,914)	$ (22,089)

Insider Trading Arrangements

Insider Trading Arrangements	3 Months Ended
	Dec. 31, 2024
Trading Arrangements, by Individual
Rule 10b5-1 Arrangement Adopted	false
Non-Rule 10b5-1 Arrangement Adopted	false
Rule 10b5-1 Arrangement Terminated	false
Non-Rule 10b5-1 Arrangement Terminated	false

Cybersecurity Risk Management,

Cybersecurity Risk Management, Strategy, and Governance	12 Months Ended
	Dec. 31, 2024
Cybersecurity Risk Management, Strategy, and Governance [Line Items]
Cybersecurity Risk Management Processes for Assessing, Identifying, and Managing Threats [Text Block]	ITEM 1C. CY BERSECURITY. Our Company places a high priority on cybersecurity, information security, and securing confidential business information and personal information that we receive and store related to our customers and employees. Our Company’s Audit Committee oversees the cybersecurity risks faced by the Company. In connection therewith, a Cybersecurity Steering Committee, which consists of our Chief Financial Officer, Chief Operating Officer, General Counsel, Vice President of Software Development, and Vice President of Regulatory Affairs , was formed to identify material risks and cybersecurity threats arising in our business. Our Audit Committee receives updates from the Cybersecurity Steering Committee at least annually, which cover topics related to information security, privacy, and cyber risks and risk management processes, including the status of significant cybersecurity incidences and projects designed to strengthen our information security posture. Our Audit Committee is also responsible for ensuring that the Board of Directors also receives periodic reports with respect to the status and management of our cybersecurity risks. The Cybersecurity Steering Committee, in collaboration with delegates from our business and functions, is responsible for implementing the Company’s enterprise-wide cyber security and information security strategy, employee training and compliance, and managing policies and processes for the Company’s information technology standards, product security, and privacy. As a member of the Cybersecurity Steering Committee, our Vice President of Software Development provides experience devising effective cybersecurity management practices in the areas of both software and product development, including risk evaluation, impact assessment, security threat modelling, cybersecurity mitigation strategies, residual risk acceptability and methodologies for security risk verification. He has led the integration of our medical device software into some of the largest hospital and research institutions in the world in compliance with the extensive cybersecurity requirements of these institutions. In addition to utilizing internal Company resources, the Cybersecurity Steering Committee also regularly consults with external advisors and specialists regarding opportunities and enhancements to strengthen its practices and policies. We also engage with third-party consultants to manage the infrastructure and security of our information technology landscape. Our cybersecurity program includes: • Penetration testing of internal information technology systems and review of program maturity based on the National Institute of Standards and Technology (“NIST”) cybersecurity framework; • Phishing, social engineering, and cyber hygiene training; • Continuous security event monitoring, management, and incident response plans; • Continuous enhancements to security capabilities based on evolving threats; • Information security policies and procedures; • Privacy controls and compliance with applicable legislative and regulatory requirements; • Assessment of applicable third-party vendors’ cybersecurity and information security practices; and • A cross-functional approach to addressing cybersecurity risk with participation from representatives across the business and functions. As part of our cybersecurity program, we have adopted an incident response plan, under which the Chairs of our Board of Directors and Audit Committee are informed by the Cybersecurity Steering Committee of any cybersecurity incidents that have the potential to materially adversely impact the Company or its information systems. To date, no attempted cyber-attack or other attempted intrusion on our information technology networks has resulted in a material adverse impact on our operations or financial results, or in any penalties or settlements.
Cybersecurity Risk Management Third Party Engaged [Flag]	true
Cybersecurity Risk Third Party Oversight and Identification Processes [Flag]	true
Cybersecurity Risk Materially Affected or Reasonably Likely to Materially Affect Registrant [Flag]	false
Cybersecurity Risk Board of Directors Oversight [Text Block]	Our Company’s Audit Committee oversees the cybersecurity risks faced by the Company. In connection therewith, a Cybersecurity Steering Committee, which consists of our Chief Financial Officer, Chief Operating Officer, General Counsel, Vice President of Software Development, and Vice President of Regulatory Affairs , was formed to identify material risks and cybersecurity threats arising in our business. Our Audit Committee receives updates from the Cybersecurity Steering Committee at least annually, which cover topics related to information security, privacy, and cyber risks and risk management processes, including the status of significant cybersecurity incidences and projects designed to strengthen our information security posture. Our Audit Committee is also responsible for ensuring that the Board of Directors also receives periodic reports with respect to the status and management of our cybersecurity risks. The Cybersecurity Steering Committee, in collaboration with delegates from our business and functions, is responsible for implementing the Company’s enterprise-wide cyber security and information security strategy, employee training and compliance, and managing policies and processes for the Company’s information technology standards, product security, and privacy. As a member of the Cybersecurity Steering Committee, our Vice President of Software Development provides experience devising effective cybersecurity management practices in the areas of both software and product development, including risk evaluation, impact assessment, security threat modelling, cybersecurity mitigation strategies, residual risk acceptability and methodologies for security risk verification. He has led the integration of our medical device software into some of the largest hospital and research institutions in the world in compliance with the extensive cybersecurity requirements of these institutions. In addition to utilizing internal Company resources, the Cybersecurity Steering Committee also regularly consults with external advisors and specialists regarding opportunities and enhancements to strengthen its practices and policies. As part of our cybersecurity program, we have adopted an incident response plan, under which the Chairs of our Board of Directors and Audit Committee are informed by the Cybersecurity Steering Committee of any cybersecurity incidents that have the potential to materially adversely impact the Company or its information systems.
Cybersecurity Risk Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our Company’s Audit Committee oversees the cybersecurity risks faced by the Company. In connection therewith, a Cybersecurity Steering Committee, which consists of our Chief Financial Officer, Chief Operating Officer, General Counsel, Vice President of Software Development, and Vice President of Regulatory Affairs , was formed to identify material risks and cybersecurity threats arising in our business. Our Audit Committee receives updates from the Cybersecurity Steering Committee at least annually, which cover topics related to information security, privacy, and cyber risks and risk management processes, including the status of significant cybersecurity incidences and projects designed to strengthen our information security posture. Our Audit Committee is also responsible for ensuring that the Board of Directors also receives periodic reports with respect to the status and management of our cybersecurity risks.
Cybersecurity Risk Process for Informing Board Committee or Subcommittee Responsible for Oversight [Text Block]	Our Audit Committee receives updates from the Cybersecurity Steering Committee at least annually, which cover topics related to information security, privacy, and cyber risks and risk management processes, including the status of significant cybersecurity incidences and projects designed to strengthen our information security posture.
Cybersecurity Risk Role of Management [Text Block]	a Cybersecurity Steering Committee, which consists of our Chief Financial Officer, Chief Operating Officer, General Counsel, Vice President of Software Development, and Vice President of Regulatory Affairs , was formed to identify material risks and cybersecurity threats arising in our business. Our Audit Committee receives updates from the Cybersecurity Steering Committee at least annually, which cover topics related to information security, privacy, and cyber risks and risk management processes, including the status of significant cybersecurity incidences and projects designed to strengthen our information security posture. Our Audit Committee is also responsible for ensuring that the Board of Directors also receives periodic reports with respect to the status and management of our cybersecurity risks. The Cybersecurity Steering Committee, in collaboration with delegates from our business and functions, is responsible for implementing the Company’s enterprise-wide cyber security and information security strategy, employee training and compliance, and managing policies and processes for the Company’s information technology standards, product security, and privacy. As a member of the Cybersecurity Steering Committee, our Vice President of Software Development provides experience devising effective cybersecurity management practices in the areas of both software and product development, including risk evaluation, impact assessment, security threat modelling, cybersecurity mitigation strategies, residual risk acceptability and methodologies for security risk verification. He has led the integration of our medical device software into some of the largest hospital and research institutions in the world in compliance with the extensive cybersecurity requirements of these institutions. In addition to utilizing internal Company resources, the Cybersecurity Steering Committee also regularly consults with external advisors and specialists regarding opportunities and enhancements to strengthen its practices and policies.
Cybersecurity Risk Management Positions or Committees Responsible [Flag]	true
Cybersecurity Risk Management Positions or Committees Responsible [Text Block]	In connection therewith, a Cybersecurity Steering Committee, which consists of our Chief Financial Officer, Chief Operating Officer, General Counsel, Vice President of Software Development, and Vice President of Regulatory Affairs , was formed to identify material risks and cybersecurity threats arising in our business.
Cybersecurity Risk Management Expertise of Management Responsible [Text Block]	As a member of the Cybersecurity Steering Committee, our Vice President of Software Development provides experience devising effective cybersecurity management practices in the areas of both software and product development, including risk evaluation, impact assessment, security threat modelling, cybersecurity mitigation strategies, residual risk acceptability and methodologies for security risk verification. He has led the integration of our medical device software into some of the largest hospital and research institutions in the world in compliance with the extensive cybersecurity requirements of these institutions.
Cybersecurity Risk Process for Informing Management or Committees Responsible [Text Block]	The Cybersecurity Steering Committee, in collaboration with delegates from our business and functions, is responsible for implementing the Company’s enterprise-wide cyber security and information security strategy, employee training and compliance, and managing policies and processes for the Company’s information technology standards, product security, and privacy. As a member of the Cybersecurity Steering Committee, our Vice President of Software Development provides experience devising effective cybersecurity management practices in the areas of both software and product development, including risk evaluation, impact assessment, security threat modelling, cybersecurity mitigation strategies, residual risk acceptability and methodologies for security risk verification. He has led the integration of our medical device software into some of the largest hospital and research institutions in the world in compliance with the extensive cybersecurity requirements of these institutions. In addition to utilizing internal Company resources, the Cybersecurity Steering Committee also regularly consults with external advisors and specialists regarding opportunities and enhancements to strengthen its practices and policies.
Cybersecurity Risk Management Positions or Committees Responsible Report to Board [Flag]	true

Description of the Business and

Description of the Business and Financial Condition	12 Months Ended
	Dec. 31, 2024
Description Of Business And Liquidity
Description of the Business and Financial Condition	1. Description of the Business and Financial Condition ClearPoint Neuro, Inc. (the “Company”) is a commercial-stage medical device company focused on the development and commercialization of innovative platforms for performing minimally invasive surgical procedures in the brain. From the Company’s inception in 1998, the Company deployed significant resources to fund its efforts to develop the foundational capabilities for enabling MRI-guided interventions, building an intellectual property portfolio, and identifying and building out commercial applications for the technologies it develops. In 2021, the Company’s efforts expanded beyond the MRI suite to encompass development and commercialization of new neurosurgical device products for the operating room setting, as well as consulting services for pharmaceutical and biotech companies, academic institutions, and contract research organizations. The Company was incorporated in the state of Delaware in March 1998, and has headquarters located in Solana Beach, California, and a manufacturing facility in Carlsbad, California. The Company established ClearPoint Neuro (Canada) Inc., a wholly owned subsidiary incorporated in Canada, in August 2013, primarily for the purpose of performing software development, and established ClearPoint Neuro U.K. Ltd, a wholly owned subsidiary incorporated in the United Kingdom, in October 2020, ClearPoint Neuro Germany GmbH., a wholly owned subsidiary incorporated in Germany, in May 2023, and ClearPoint Neuro Italy, S.r.l., a wholly owned subsidiary incorporated in Italy, in August 2023, primarily for the purpose of employing the Company’s clinical services representatives serving the Company’s customers in the United Kingdom and the EU. The activities of all subsidiaries are reflected in these consolidated financial statements. The Company’s initial product offering, the ClearPoint system, is an integrated system comprised of capital equipment and disposable products, designed to allow minimally invasive procedures in the brain to be performed in an MRI suite. The ClearPoint Array Neuro Navigation System and its principal disposable component, introduced in 2021, is designed to be deployed in an operating room setting while also being usable in an MRI suite. Both systems provide guidance for the placement and operation of instruments or devices during the planning and operation of neurosurgical procedures. The Company received 510(k) clearance from the U.S. Food and Drug Administration (“FDA”) in 2010 to market the ClearPoint system in the United States for general neurosurgical interventional procedures; in February 2011, the Company also obtained CE marking for its ClearPoint system. In 2011 and 2018, the Company received 510(k) clearance and CE marking, respectively, for its SmartFlow cannula which is being used, or is under evaluation, along with the Company's services, by more than 60 pharmaceutical and biotech companies, academic institutions, or contract research organizations having a focus on biologics and drug delivery. The Company provides consulting services to pharmaceutical and other medical technology customers for improving outcome predictability and optimizing preclinical and clinical workflows. The Company's expertise is concentrated in benchtop testing, preclinical studies, clinical trial support, regulatory consultation, and over-arching translation from the preclinical to the clinical setting to enhance accuracy and precision of drug delivery. In September 2022, the ClearPoint Prism Neuro Laser Therapy System, for which the Company has exclusive global commercialization rights, received 510(k) clearance through the Company’s Swedish partner CLS. The Prism laser represents the Company's first therapy product offering. Macroeconomic Trends The Company continues to monitor the impacts of various macroeconomic trends, such as inflationary pressure, changes in monetary policy, decreasing consumer confidence and spending, the introduction of or changes in tariffs or trade barriers, and global or local recession. Such changes in domestic and global macroeconomic conditions may lead to increased costs for the Company's business. Additionally, these macroeconomic trends could adversely affect the Company's customers, which could impact their willingness to spend on the Company's products and services, or their ability to make payments, which could harm the Company's collection of accounts receivable and financial results. The world’s financial markets remain susceptible to significant stresses, resulting in reductions in available credit and government spending, economic downturn or stagnation, foreign currency fluctuations and volatility in the valuations of securities generally. As a result, the Company's ability to access capital markets and other funding sources in the future may not be available on commercially reasonable terms, if at all. The rapid development and fluidity of these situations precludes any prediction as to the ultimate impact they will have on the Company's business, financial condition, results of operation and cash flows, which will depend largely on future developments. Liquidity The Company has incurred net losses since its inception which has resulted in a cumulative deficit at December 31, 2024 of $ 191.4 million . In addition, the Company’s use of cash from operations amounted to $ 9.0 million for the year ended December 31, 2024. Since inception, the Company has financed its operations principally from the sale of equity securities and the issuance of notes payable. In March 2024, the Company completed a follow-on public offering of 2,653,848 shares of its common stock from which the net proceeds totaled approximately $ 16.2 million after deducting payment of underwriting discounts and commissions and other offering expenses. In November 2024, the Company entered into an At-the-Market Equity Offering Sales Agreement with an investment banking firm (the “ ATM Agreement ”) pursuant to which it may offer and sell, from time to time, shares of its common stock, having aggregate sales proceeds of up to $ 50 million, subject to the terms and conditions of the ATM Agreement. As of December 31, 2024 , the Company had no t issued any shares of common stock under the ATM Agreement. Additional information with respect to these offerings is found in Note 9. In August 2024, the Company repaid in full the remaining $ 10 million outstanding under the Securities Purchase Agreement (“SPA”) entered into in 2020, pursuant to which it issued secured convertible notes to two investors raising gross proceeds of $ 25 million, of which $ 15 million had been previously converted to common stock. Additional information with respect to these notes is found in Note 7. As required by accounting principles generally accepted in the United States (“GAAP”), the Company has evaluated its ability to continue as a going concern and has determined that based on current forecasts, existing cash and cash equivalent balances at December 31, 2024 are sufficient to support the Company’s operations and meet its obligations for at least the next twelve months.

Summary of Significant Accounti

Summary of Significant Accounting Policies	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Significant Accounting Policies	2. Summary of Significant Accounting Policies Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated. Basis of Presentation and Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from those estimates. Cash and Cash Equivalents Cash and cash equivalents include all highly liquid investments with an original maturity of three months or less from the date of purchase. As of December 31, 2024 , cash equivalents consisted predominantly of U.S. Government debt securities. Inventory Inventory is carried at the lower of cost or net realizable value. The costs of inventory are determined using the standard cost method, which approximates actual cost based on a first-in, first-out method. Items in inventory relate primarily to the Company’s ClearPoint system and related disposables. Software license inventory related to ClearPoint systems undergoing on-site customer evaluation is included in inventory in the accompanying consolidated balance sheets. All other software license inventory is classified as a non-current asset. The Company periodically reviews its inventory for obsolete items and provides a reserve upon identification of potential obsolete items. Intangible Assets The Company is a party to a license agreement that provides rights to the Company for the development and commercialization of products. Under the term of the license agreement, the Company paid an aggregate $ 1.1 million to the licensor upon execution of the license agreement for access to the underlying technology and will make future payments based on the achievement of regulatory and commercialization milestones as defined in the license agreement. In 2022, the Company made a payment of $ 0.6 million to the licensor for the achievement of a regulatory milestone, which acts as a prepayment for future royalties. In conformity with ASC 350, “Intangibles – Goodwill and Other,” the Company amortizes its investment in the upfront license rights described above over an expected useful life of up to five years , or as commercial sales occur for the royalty prepayment. In addition, the Company periodically evaluates the recoverability of its investment in the license rights and records an impairment charge in the event such evaluation indicates that the Company's investment is not likely to be recovered. Property and Equipment Property and equipment are recorded at cost and are depreciated on a straight-line basis over their estimated useful lives, principally three to seven years . Leasehold improvements are depreciated on a straight-line basis over the lesser of their estimated useful lives or the term of the related lease. Impairment of Long-Lived Assets The Company periodically evaluates the recoverability of its long-lived assets (finite-lived intangible assets and property and equipment). Whenever events or changes in circumstances indicate that the carrying amount of such assets may not be fully recoverable, the expected undiscounted future cash flows are compared to the net book value of the related assets. If the net book value of the related assets were to exceed the undiscounted expected future cash flows of the assets, the carrying amount would be reduced to the present value of the expected future cash flows and an impairment loss would be recognized. Revenue Recognition The Company’s revenue is comprised primarily of: (1) product revenue resulting from the sale of neurosurgery, navigation, therapy, biologics and drug delivery disposable products, and the sale of ClearPoint capital equipment and software; and (2) service revenue resulting from development services and consultation revenue in connection with customer-sponsored preclinical and clinical trials, as well as revenue resulting from the service, installation, training, and shipping related to ClearPoint capital equipment and software. The Company recognizes revenue when (i) control of the Company’s products is transferred to its customers or (ii) services are provided to customers, each in an amount that reflects the consideration the Company expects to receive from its customers in exchange for those products and services, in a process that involves identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the distinct performance obligations in the contract, and recognizing revenue when or as the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. When a contract calls for the satisfaction of multiple performance obligations for a single contract price, the Company typically allocates the contract price among the performance obligations based on the relative stand-alone selling prices for each such performance obligation customarily charged by the Company. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control. Lines of Business; Timing of Revenue Recognition Product Revenue: • Neurosurgery navigation product, biologics and drug delivery systems product, and therapy product sales: Revenue from the sale of neurosurgery navigation products (consisting of disposable products sold commercially and related to cases utilizing the Company's ClearPoint system), biologics and drug delivery systems (consisting primarily of disposable products related to customer-sponsored clinical trials utilizing the ClearPoint system), and therapy products (consisting primarily of disposable laser-related products used in neurosurgical procedures) is generally based on customer purchase orders, the predominance of which require delivery within one week of the order having been placed, and is generally recognized at the point in time of shipping to the customer, which is the point at which legal title, and risks and rewards of ownership, transfer to the customer. For certain customers, legal title and risks and rewards of ownership transfer upon delivery to the customer as stated in their respective contracts, in which case revenue is recognized upon delivery. • Capital equipment and software sales: ◦ Capital equipment and software sales preceded by evaluation periods: The predominance of capital equipment and software sales (consisting of integrated computer hardware and software that are integral components of the Company's ClearPoint system) are preceded by customer evaluation periods. During these evaluation periods, installation of, and training of customer personnel on, the systems have been completed and the systems have been in operation. Accordingly, revenue from capital equipment and software sales following such evaluation periods is recognized at the point in time that the Company is in receipt of an executed purchase agreement or purchase order. ◦ Capital equipment and software sales not preceded by evaluation periods: Revenue from sales of capital equipment and software not having been preceded by an evaluation period is recognized upon delivery to the customer and installation. For capital equipment that does not require installation, revenue is recognized upon shipment, however, for those customers where legal title and risks and rewards of ownership transfer upon delivery, revenue is recognized at such time. For both types of capital equipment and software sales described above, the determination of the point in time at which to recognize revenue represents that point at which the customer has legal title, physical possession, and the risks and rewards of ownership, and the Company has a present right to payment. Service Revenue: • Neurosurgery navigation and therapy services: The Company recognizes revenue for such services over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. • Biologics and drug delivery services and other revenue: ◦ Consultation and Development Services: The Company recognizes consultation and development service revenue over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. The Company may use output methods, such as time elapsed, or input methods, such as labor hours expended or costs incurred, to measure progress depending on which better depicts the transfer of control to the customer. ◦ License fees: The Company grants licenses to customers to develop and commercialize its SmartFlow cannula devices with the customers' proprietary biologics as a combination device. License fees represent the use of functional intellectual property as it exists at the point in time at which the license is granted and does not require any significant development or customization. Accordingly, the Company recognizes license revenue at the point in time in which the license becomes effective and the intellectual property is made available to the customer. ◦ Milestone fees : Event-based payments which are subject to the customer's achievement of specified development or regulatory milestones are included in the transaction price if, in the Company's judgment, it is probable that these milestones will be achieved and a significant future reversal of cumulative revenue under the contract will not occur. The Company re-evaluates the probability of achievement of such milestone at the end of each reporting period and adjusts the transaction price as necessary. • Capital equipment-related services: ◦ Equipment service: Revenue from service of ClearPoint capital equipment and software previously sold to customers is based on agreements with terms ranging from one to three years and is recognized ratably on a monthly basis over the term of the service agreement. A time-elapsed output method is used for service revenue because the Company transfers control evenly by providing a stand-ready service. The Company may also enter into contracts with customers who own ClearPoint capital equipment, which bundle maintenance and support services and access to software and hardware upgrades made commercially available over the term of the contract, for a single contract price, typically paid on an annual basis. The Company allocates the contract price among the performance obligations based on the relative stand-alone prices for each such performance obligation and recognizes the revenue ratably on a monthly basis. A time-elapsed output method is used as the Company is providing a stand-ready service for each of the performance obligations. ◦ Installation, training, and shipping: Consistent with the Company's recognition of revenue for capital equipment and software sales as described above, fees for installation, training, and shipping in connection with sales of capital equipment and software that have been preceded by customer evaluation periods are recognized as revenue at the point in time the Company is in receipt of an executed purchase order for the equipment and software. Installation, training, and shipping fees related to capital equipment and software sales not having been preceded by an evaluation period are recognized as revenue concurrent with the recognition of revenue of the related capital equipment. Payment terms under contracts with customers generally are in a range of 30 - 60 days after the customers’ receipt of the Company’s invoices. The Company's terms and conditions do not provide for a right of return unless for: (a) product defects; or (b) other conditions subject to the Company's approval. See Note 3 for additional information regarding revenue recognition. Research and Development Costs Costs related to research, design and development of products are charged to research and development expense as incurred. Income Taxes Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Such assets and liabilities are measured using enacted tax rates expected to apply to taxable income or loss in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates is recognized in the period that includes the enactment date. The Company provides a valuation allowance against net deferred income tax assets unless, based upon available evidence, it is more likely than not the deferred income tax assets will be realized. The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense. As of December 31, 2024 and 2023 , the Company had no accrued interest or penalties related to uncertain tax positions. Net Loss Per Share The Company computes net loss per share using the weighted-average number of common shares outstanding during the period. Basic and diluted net loss per share are the same because the conversion, exercise or issuance of all potential common stock equivalents, which comprise the entire amount of the Company’s outstanding common stock options and unvested RSUs as described in Note 9, would be anti-dilutive, due to the reporting of a net loss for each of the periods in the accompanying consolidated statements of operations. For the years ended December 31, 2024 and 2023, approximately 3 million and 4 million shares, respectively, of common stock equivalents were excluded from the calculation of diluted net loss per common share because their effect was anti-dilutive. Share-Based Compensation The Company accounts for compensation for all arrangements under which employees, directors and others receive shares of stock or other equity instruments (such as restricted stock units and options) based on fair value. The fair value of each award is estimated as of the grant date and amortized as compensation expense over the requisite vesting period. Forfeitures are recognized as they occur. In the case of stock options, the fair value is estimated on the grant dates using the Black-Scholes valuation model. This valuation model requires the input of highly subjective assumptions, including the expected stock volatility, estimated award terms and risk-free interest rates for the expected terms. To estimate the expected terms, the Company utilizes the simplified method for “plain vanilla” options discussed in the Staff Accounting Bulletin 107 (“SAB 107”) issued by the SEC. The Company believes that all factors listed within SAB 107 as pre-requisites for utilizing the simplified method apply to the Company and its share-based compensation arrangements. The Company intends to utilize the simplified method for the foreseeable future until more detailed information about exercise behavior becomes available. Expected volatility is based on historical volatility of the Company's common stock. The Company utilizes risk-free interest rates based on U.S. treasury instruments, the terms of which are consistent with the expected terms of the equity awards. The Company has not paid and does not anticipate paying cash dividends on its shares of common stock; therefore, the expected dividend yield is assumed to be zero . The Company did no t grant any stock options in 2024. Fair Value Determination of Share-Based Transactions The Company’s common stock is traded on the Nasdaq Capital Market under the symbol “CLPT.” Quoted closing stock prices are used as a key input in determining the fair value for share-based transactions. Concentration Risks and Other Risks and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company holds substantially all its cash and cash equivalents on deposit with financial institutions in the U.S. that are insured by the Federal Deposit Insurance Corporation or in U.S. government debt securities. At December 31, 2024, the Company had approximately $ 1.2 million in bank balances that were in excess of the insured limits. At December 31, 2024, there were two customers whose accounts receivable balances aggregated to 24 % of accounts receivable at that date. At December 31, 2023, there were four customers whose accounts receivable balances aggregated to 80 % of accounts receivable at that date. One pharmaceutical customer, a related party that is a stockholder, former noteholder, and whose chief executive officer is a representative on the Company's Board of Directors, for whom the Company provides hardware, software, clinical services, and market development services in support of the customer's clinical trials, and from whom the Company earns a quarterly fee, accounted for 9 % of total revenue for the year ended December 31, 2024 , and of 12 % total revenue for the year ended December 31, 2023 . There were no outstanding receivables from this customer at December 31, 2024 or December 31, 2023. Prior to granting credit, the Company generally performs credit evaluations of its customers’ financial condition. In general, the Company does not require collateral from customers with an extension of credit. The accounts receivable balance is reduced by an allowance for credit losses from the potential inability of the Company's customers to make required payments. The allowance for credit losses at December 31, 2024 and 2023 was $ 1.1 million and $ 1.4 million , respectively. The Company evaluates the historic loss experience on the accounts receivable balance and also considers separately customers with receivable balances that may be negatively impacted by current economic developments and market conditions. The estimate is a result of the Company's ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations. The Company is subject to risks common to emerging companies in the medical device industry, including, but not limited to: new technological innovations; acceptance and competitiveness of its products; dependence on key personnel; dependence on key suppliers; its ability to maintain its third-party collaboration, license and joint development partners; changes in general economic conditions and interest rates; its ability to obtain additional funding to support its business; regulatory uncertainty; protection of proprietary technology; compliance with changing government regulations; uncertainty of widespread market acceptance of products; access to credit for capital purchases by customers; and product liability claims. Certain components used in manufacturing have relatively few alternative sources of supply and establishing additional or replacement suppliers for such components cannot be accomplished quickly. The inability of any of these suppliers to fulfill the Company’s supply requirements may negatively impact future operating results. Recent Accounting Standards Adopted In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” The amendments improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The Company adopted the ASU on its annual reporting for the year ended December 31, 2024. See Note 10 in the accompanying notes to the consolidated financial statements for further detail. In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326),” which replaces the previous incurred loss impairment methodology for most financial assets with the current expected credit loss, or CECL, methodology. The new guidance requires entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. The Company adopted the new standard effective January 1, 2023 , which did not have a material impact to the consolidated financial statements. Recent Accounting Standards Not Yet Adopted In December 2023, the FASB issued ASU 2023-09, “Improvements to Income Tax Disclosures,” which requires that an entity, on an annual basis, disclose additional income tax information, primarily related to the rate reconciliation and income taxes paid. The provisions of the ASU are intended to enhance the transparency and decision usefulness of income tax disclosures. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively and is effective for calendar year-end public business entities in the 2025 annual period and in 2026 for interim periods with early adoption permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements. In November 2024, the FASB issued ASU 2024-03, “Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,” which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. The new disclosure requirements are effective for the Company's annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of this pronouncement on its related disclosures.

Revenue Recognition

Revenue Recognition	12 Months Ended
	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Revenue Recognition	3. Revenue Recognition Revenue by Service Line Years Ended December 31, (in thousands) 2024 2023 Biologics and drug delivery Disposable products $ 5,606 $ 2,154 Services and license fees 11,704 11,448 Subtotal – Biologics and drug delivery revenue 17,310 13,602 Neurosurgery navigation and therapy Disposable products 10,285 7,589 Services — 931 Subtotal – Neurosurgery navigation and therapy revenue 10,285 8,520 Capital equipment and software Systems and software products 2,735 860 Services 1,060 973 Subtotal – Capital equipment and software revenue 3,795 1,833 Total revenue $ 31,390 $ 23,955 Contract Balances • Contract assets – The timing of revenue recognition may differ from the time of billing to the Company's customers. In most cases, customers are billed upon shipment of such products or delivery of such services and the related contract assets, which represent an unconditional right to consideration and comprise the accounts receivable balance. When revenue is recognized in advance of its right to bill and receive consideration, the Company records this unbilled receivable as a contract asset, which is classified as other current assets in the accompanying consolidated balance sheets. Additionally, at December 31, 2022, the Company recorded as a contract asset up-front costs for direct materials incurred to fulfill a customer contract. Such costs were recognized as expense in 2023. (in thousands) December 31, 2024 December 31, 2023 December 31, 2022 Accounts receivable, net $ 4,713 $ 3,211 $ 2,665 Other contract assets Unbilled receivables $ 642 $ 733 $ 43 Deferred contract costs $ — $ — $ 327 • Contract liabilities – Contract liabilities consist of amounts that have been invoiced and for which the Company has the right to bill, but that have not been recognized as revenue as the related goods or services have not been transferred. The Company's contract liabilities are generally comprised of the following (1) capital equipment and software-related service fees that are typically billed and collected at the inception of the service agreements, which have terms ranging from one to three years ; (2) annual fees for agreements with customers that bundle the capital equipment and software-related service fees with software and hardware upgrades that are made commercially available over the term of the contract; and (3) up-front payments from customers made in connection with consulting services. The unearned portion of all such fees is classified as deferred revenue. At December 31, 2022, the Company also had a $ 0.5 million refund liability resulting from an up-front customer payment which was potentially refundable if the parties did not enter into the ensuing agreement. In 2023, the uncertainties underlying this amount were resolved and the amount was recognized as revenue. (in thousands) December 31, 2024 December 31, 2023 December 31, 2022 Deferred revenues $ 2,557 $ 3,154 $ 1,457 Refund liability $ — $ — $ 500 During the years ended December 31, 2024 and 2023, the Company recognized capital equipment and software-related service revenue of approximately $ 2.3 million and $ 1.1 million , respectively, which was previously included in deferred revenue in the accompanying consolidated balance sheets at December 31, 2023 and 2022, respectively. Transaction price allocated to remaining performance obligations represents contracted revenue that has not yet been recognized, which includes deferred revenue that will be recognized as revenue in future periods. The majority of the remaining performance obligations relate to capital equipment and software-related service agreements and the upfront payments discussed under the heading “Contract Balances” above, which amounted to approximately $ 2.5 million at December 31, 2024. The Company expects to recognize approximately 83 % of this revenue over the next twelve months and the remainder thereafter.

Fair Value Measurement

Fair Value Measurement	12 Months Ended
	Dec. 31, 2024
Fair Value Disclosures [Abstract]
Fair Value Measurement	4. Fair Value Measurement Fair value measurements are based on a three-tier hierarchy that prioritizes the inputs used to measure fair value. These tiers include: Level 1, defined as observable inputs such as quoted market prices in active markets; Level 2, defined as inputs other than quoted prices included within Level 1 that are observable for the asset or liability, either directly or indirectly; and Level 3, defined as unobservable inputs for which little or no market data exists, therefore requiring an entity to develop its own assumptions. The fair value of cash and cash equivalents of $ 20.1 million and $ 23.1 million as of December 31, 2024, and December 31, 2023 , respectively, is derived using Level 1 inputs. The cash equivalents are comprised of short-term bank deposits, money market funds, and U.S. Government debt securities with original maturities of three months or less, for which the Company believes that the carrying value is a reasonable estimate of fair value.

Inventory

Inventory	12 Months Ended
	Dec. 31, 2024
Inventory Disclosure [Abstract]
Inventory	5. Inventory Inventory consists of the following as of December 31: (in thousands) 2024 2023 Raw materials and work in process $ 5,503 $ 6,466 Software licenses 265 211 Finished goods 1,095 1,234 Inventory included in current assets 6,863 7,911 Software licenses – non-current 103 386 $ 6,966 $ 8,297 Inventory balances are presented net of an excess and obsolete reserve totaling $ 2.3 million and $ 2.0 million at December 31, 2024 and 2023 , respectively.

Property and Equipment

Property and Equipment	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Property and Equipment	6. Property and Equipment Property and equipment consist of the following as of December 31: (in thousands) 2024 2023 Equipment $ 1,558 $ 1,108 Leasehold improvements 485 485 Loaned systems 1,305 741 3,348 2,334 Less accumulated depreciation and amortization ( 1,343 ) ( 945 ) Total property and equipment, net $ 2,005 $ 1,389 Depreciation and amortization expense related to property and equipment for each of the years ended December 31, 2024 and 2023 was $ 0.2 million . Loaned systems are ClearPoint systems that are in operation at customer sites on an evaluation basis.

Notes Payable

Notes Payable	12 Months Ended
	Dec. 31, 2024
Debt Disclosure [Abstract]
Notes Payable	7. Notes Payable In January 2020, the Company completed a financing transaction with two investors (the “2020 Convertible Noteholders”), whereby the Company issued an aggregate principal amount of $ 17.5 million of secured convertible notes (the “First Closing Notes”) pursuant to the SPA, which, unless earlier converted or redeemed, were to mature on January 29, 2025, and bore interest at a rate equal to the sum of (i) the greater of (a) the three (3)-month Secured Overnight Financing Rate (“SOFR”) and (b) two percent ( 2 %), plus (ii) a margin of 2 % on the outstanding balance of the First Closing Notes, payable quarterly on the first business day of each calendar quarter. The First Closing Notes were convertible at a price of $ 6.00 per share, subject to certain adjustments set forth in the SPA and the note agreement and could not be prepaid without the consent of the noteholder. In May 2021, one of the 2020 Convertible Noteholders (the “Converting Noteholder”) converted the entire $ 7.5 million principal amount of such Converting Noteholder’s First Closing Note, and related accrued interest of approximately $ 0.04 million, into 1,256,143 shares of the Company’s common stock. In December 2020, the Company issued the Second Closing Note (as defined in the SPA) to one of the 2020 Convertible Noteholders in an aggregate principal amount of $ 7.5 million. In November 2021, the holder of the Second Closing Note converted the entire $ 7.5 million principal amount of such note, along with related accrued and payment in-kind interest aggregating $ 0.3 million, into 773,446 shares of the Company's common stock. On August 23, 2024, the Company repaid all amounts owing under the remaining First Closing Note, which included the principal amount of $ 10.0 million , and related accrued interest of $ 0.1 million . In connection with the prepayment, the noteholder waived all prohibitions on prepayment of the note, and all collateral securing the note was released. The estimated fair value of the First Closing Note, developed based on inputs classified as Level 3 within the fair value hierarchy, was approximately $ 12.5 million as of December 31, 2023.

Commitments and Contingencies

Commitments and Contingencies	12 Months Ended
	Dec. 31, 2024
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	8. Commitments and Contingencies Operating Leases The Company subleases office space in Solana Beach, California that serves as its corporate headquarters and houses certain management and personnel. The sublease term commenced on December 15, 2020, is set to expire on December 31, 2026, and is renewable for an additional five-year period, at the Company’s option, provided that the Company’s landlord has entered into an extension of its prime lease for the office space that encompasses the Company’s office space for at least five years . The Company also leases space in Carlsbad, California, that houses office space and a manufacturing facility under a lease that commenced on June 1, 2023 and ends on May 31, 2033. The Company has two options to extend the lease term for thirty-six or sixty months , at the fair market rental value. Upon establishment of the new manufacturing facility in Carlsbad, the Company terminated its prior manufacturing facility lease in Irvine, California, effective October 2023. The lease termination did not have a material impact on the consolidated financial statements. The optional renewal periods for both leases are not considered in the determination of the right-of-use asset or the lease liability as the Company does not consider it reasonably certain that it would exercise either of such options. The lease arrangements contain lease components and non-lease components which are accounted for as a single lease component as the Company has elected the practical expedient to group lease and non-lease components for all leases. Operating lease liabilities are based on the net present value of the remaining lease payments over the remaining lease term. In determining the present value of lease payments, the Company used the published U.S. High Yield CCC corporate bond rates at the lease commencement date of the Solana Beach lease and the current estimate of the Company's incremental borrowing rate at the lease commencement date of the Carlsbad lease. The weighted average remaining lease term of the Company's operating leases was 6.81 years and 7.38 years, and the weighted average discount rate used to determine the operating lease liability was 12 % and 11.8 % , as of December 31, 2024 and 2023, respectively. The lease cost was $ 0.9 million and $ 0.6 million for the years ended December 31, 2024 and 2023, respectively. As of December 31, 2024, future minimum lease payments are as follows: Years ending December 31, (in thousands) 2025 $ 954 2026 985 2027 502 2028 520 2029 538 Thereafter 1,981 Total minimum payments 5,480 Less: Discount to present value of lease payments ( 1,912 ) Discounted present value of lease payments $ 3,568 Purchase Commitments The Company is a party to various purchase arrangements related to its manufacturing and research and development activities. At December 31, 2024 there was approximately $ 1.2 million of open purchase orders and contractual obligations in the ordinary course of business, the majority of which are due within one year . Additionally, the Company is also a party to a license and collaboration agreement which requires minimum purchase commitments for a seven-year period starting in 2023. The total remaining minimum purchase commitments related to this agreement is $ 4.2 million over the next five years . Legal Contingencies The Company was named as a defendant to a lawsuit filed by a patient who suffered an adverse outcome in connection with a surgical procedure in which the Company’s ClearPoint Navigation System was used, seeking damages in an unspecified amount with respect to the Company. The plaintiff also named as defendants the health care provider performing the surgical procedure and another medical device manufacturer whose product was also used in the procedure. A global demand of all defendants in this case has been made by the plaintiff in the amount of $ 13.6 million. Discovery for the lawsuit is currently in process. Based on the Company’s investigation to date, the Company believes that the claims against the Company in this lawsuit are without merit and intends to defend the lawsuit vigorously. The Company has tendered the claim to its Medical Technology Solutions policy insurer. The Company is unable to estimate the probable loss or range of loss that could potentially result from this lawsuit and will continue to evaluate information as it becomes known and will record an estimate for losses at the time when it is both probable that a loss has been incurred and the amount of the loss is reasonably estimable. Legal fees incurred by the Company are expensed in the period incurred.

Stockholders' Equity

Stockholders' Equity	12 Months Ended
	Dec. 31, 2024
Equity [Abstract]
Stockholders' Equity	9. Stockholders’ Equity 2024 Public Offering In March 2024, the Company completed a follow-on public offering of 2,653,848 shares of its common stock, composed of 2,307,694 shares of common stock offered at a public offering price of $ 6.50 per share and an additional 346,154 shares of common stock pursuant to the exercise of the underwriters' option to purchase additional shares at the public offering price. Net proceeds from the offering total approximately $ 16.2 million after deducting underwriting discounts and commissions, and other offering expenses paid by the Company. The underwriting agreement contains representations, warranties, agreements and indemnification obligations by the Company that are customary for this type of transaction. 2024 At-The-Market ( “ ATM ” ) Equity Offering In November 2024, the Company entered into the ATM Agreement to, from time to time, sell shares of its common stock having aggregate sales proceeds of up to $ 50 million, subject to the terms and conditions of the ATM Agreement. As of December 31, 2024 , the Company did no t issue any shares of common stock under the ATM Agreement. Equity Compensation Plans In May 2024, the Company's stockholders approved the Fifth Amended and Restated 2013 Incentive Compensation Plan (the “2013 Plan”) under which the Company currently grants stock options, restricted stock awards, and restricted stock units. The total shares of the Company’s common stock reserved for issuance under the 2013 Plan is 6,106,250 , of which unvested awards covering 2,749,616 shares were outstanding as of December 31, 2024 and 1,230,813 shares remained available for grants under the 2013 Plan as of that date. Share-Based Compensation Expense The Company records share-based compensation expense on a straight-line basis over the related vesting period and recognizes forfeitures as they occur. The following table sets forth share-based compensation expense included in the consolidated statements of operations: Years Ended December 31, (in thousands) 2024 2023 Cost of revenue $ 112 $ 101 Research and development 1,641 1,352 Sales and marketing 1,881 1,717 General and administrative 3,273 2,909 Share-based compensation expense $ 6,907 $ 6,079 Share-based compensation expense by type of share-based award: Years Ended December 31, (in thousands) 2024 2023 Stock options $ 653 $ 956 RSAs and RSUs 6,066 4,903 ESPP 188 220 $ 6,907 $ 6,079 Total unrecognized compensation expense by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted): December 31, 2024 Unrecognized Remaining Stock options $ 300 0.92 RSAs and RSUs $ 7,815 1.68 Stock Option Activity Options granted under the 2013 Plan must have an exercise price equal to at least 100 % of fair market value of the Company's common stock on the date of grant. The options generally have a maximum contractual term of ten years and vest in accordance with the individual award agreements. Stock option activity under all of the Company’s Plans as of and for the year ended December 31, 2024 is summarized below: Stock Weighted- Weighted- Intrinsic (1) Outstanding at December 31, 2023 1,478,157 $ 8.40 Exercised ( 19,090 ) $ 5.21 Forfeited or expired ( 82,671 ) $ 41.12 Outstanding at December 31, 2024 1,376,396 $ 6.48 4.70 $ 13,217 Exercisable at December 31, 2024 1,252,409 $ 6.22 4.38 $ 12,444 Vested and expected to vest at December 31, 2024 1,376,396 $ 6.48 4.70 $ 13,217 (1) Intrinsic value is calculated as the estimated fair value of the Company’s stock at December 31, 2024 less the option exercise price of in-the-money options. A summary of the status of the Company’s non-vested stock options for the year ended December 31, 2024 is presented below: Non-vested Stock Weighted- Nonvested, December 31, 2023 226,215 $ 7.37 Vested ( 95,544 ) $ 8.09 Forfeited ( 6,684 ) $ 7.05 Nonvested, December 31, 2024 123,987 $ 6.83 The weighted-average grant-date fair value of stock options granted during the year ended December 31, 2023 was $ 5.85 per share. There were no stock options granted during 2024. The total intrinsic value of stock options exercised during both the years ended December 31, 2024 and 2023 was $ 0.1 million and represents the difference between the exercise price of the option and the fair value of the common stock on the dates exercised. The total grant-date fair value of stock options vested during each of the years ended December 31, 2024 and 2023 was $ 0.8 million and $ 0.9 million , respectively. The exercise price of stock options granted is equal to the closing price of the common stock on the date of grant. The fair value of each stock option is estimated on the date of grant using the Black-Scholes valuation model utilizing the following weighted average assumptions for options granted during the years ended December 31, 2024 and 2023: Years Ended December 31, 2024 2023 Risk-free interest rate — 4.17 % Expected life (in years) — 6.10 Estimated volatility — 81.21 % Expected dividends — None Restricted Stock Activity The Company issues Restricted Stock Awards (“RSAs”) and Restricted Stock Units (“RSUs”). RSAs are grants that entitle the holder to acquire shares of the Company's common stock at zero cost. The shares covered by a RSA cannot be sold, transferred, pledged, assigned or otherwise disposed of until the award vests. A RSU is a promise by the Company to issue a share of its common stock upon vesting of the unit. Both RSAs and RSUs vest in annual installments over a two to three-year period, contingent on the holder's continued employment with the Company. Annual grants of restricted stock to the Board of Directors typically vest in one year . RSA activity as of and for the year ended December 31, 2024 is summarized below ( no RSAs were granted in 2024): Restricted Stock Weighted- Outstanding at December 31, 2023 376,914 $ 12.02 Vested ( 212,583 ) $ 12.67 Forfeited or expired ( 10,121 ) $ 11.97 Outstanding at December 31, 2024 154,210 $ 11.12 RSU activity as of and for the year ended December 31, 2024 is summarized below: Restricted Stock Weighted- Outstanding at December 31, 2023 768,139 $ 8.15 Granted 1,202,228 $ 6.18 Vested ( 270,673 ) $ 8.01 Forfeited or expired ( 41,934 ) $ 7.65 Outstanding at December 31, 2024 1,657,760 $ 6.76 The estimated fair value of the restricted stock is based on the closing market value of the Company's common stock on the date of grant. The total fair value of RSAs and RSUs vested during the years ended December 31, 2024 and 2023 was $ 4.9 million and $ 3.1 million , respectively. Employee Stock Purchase Plan On June 3, 2021, the Company's stockholders adopted and approved the ClearPoint Neuro, Inc. Employee Stock Purchase Plan (the “ESPP”). A total of 400,000 shares of the Company’s common stock are available for issuance pursuant to the terms of the ESPP. The ESPP provides eligible employees the opportunity to purchase shares of common stock at the lower of 85 % of the fair market value on either the first day or the last day of the applicable offering period, by having withheld from their salary an amount up to 15 % of their compensation. No employee may purchase more than $ 25,000 worth of common stock (calculated at the time the purchase right is granted) in any calendar year, nor may any employee purchase more than 3,500 shares in any six-month purchase period. The initial six-month purchase period commenced in July 2021. There are 138,998 shares remaining available for grant under the ESPP as of December 31, 2024. The ESPP is deemed to be compensatory, and therefore, ESPP expense has been included in share-based compensation expenses in the consolidated statements of operations for the years ended December 31, 2024 and 2023. During the year ended December 31, 2024, 97,093 shares were purchased at an average per share price of $ 4.56 . The fair value of the purchase options under the ESPP are estimated at the beginning of the purchase period using the Black-Scholes valuation model utilizing the following assumptions: 2024 2023 Risk-free interest rate 5.24 % - 5.37 % 4.77 % - 5.53 % Expected life (in years) 0.5 0.5 Estimated volatility 64.5 % - 67.33 % 61.41 % - 62.37 % Expected dividends None None The weighted-average fair value per ESPP purchase right during the years ended December 31, 2024 and 2023 was $ 2.10 per share and $ 2.57 per share, respectively.

Segment Disclosures

Segment Disclosures	12 Months Ended
	Dec. 31, 2024
Segment Reporting [Abstract]
Segment Disclosures	10. Segment Disclosures The Company is a device, cell, and gene-therapy enabling company offering precise navigation to the brain, and provides clinical products and preclinical development services for controlled drug and device delivery. The Company's operations are based in, and revenues are derived predominantly in, the United States, and business activities are managed on a consolidated basis. The Company operates in one reportable segment. The Company's Chief Executive Officer is the Chief Operating Decision Maker (“CODM”). The CODM regularly reviews disaggregated revenue data by product line as disclosed in Note 3; however, consolidated net income is utilized as the measure of profit and loss to assess performance of the business and determination on how to allocate resources. Significant expenses within net income include cost of revenue, research and development, sales and marketing, and general and administrative expenses, which are each separately presented on the Company's Consolidated Statements of Operations. Segment asset information is not used by the CODM to allocate resources.

Income Taxes

Income Taxes	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Income Taxes	11. Income Taxes The Company is subject to multiple state minimum income tax expense for the years ended December 31, 2024 and 2023 . Due to uncertainties surrounding the realization of its deferred income tax assets in future periods, the Company has recorded a 100 % valuation allowance against its net deferred income tax assets. If it is determined in the future that it is more likely than not that any deferred income tax assets are realizable, the valuation allowance will be reduced by the estimated net realizable amounts. Years Ended December 31, (in thousands) 2024 2023 Income tax benefit at federal statutory rate $ ( 3,992 ) $ ( 4,584 ) Adjustments for tax effects of: State income tax, net of federal benefit ( 650 ) ( 1,191 ) Permanent adjustments 305 49 Benefit state rate change 136 ( 23 ) Other 144 152 Share-based compensation 1,336 520 Net operating loss write-off 216 ( 574 ) Change in valuation allowance 2,517 5,659 Income tax expense $ 12 $ 8 The tax effect of temporary differences and carryforwards that give rise to significant portions of the deferred income tax assets are as follows: Years Ended December 31, (in thousands) 2024 2023 Deferred income tax assets: Net operating loss carryforwards $ 31,776 $ 30,145 Share-based compensation 1,390 2,193 Accrued expenses 295 319 174 Capitalization 4,606 3,026 Other 267 170 38,334 35,853 Less valuation allowance ( 38,333 ) ( 35,815 ) Total deferred income tax assets 1 38 Deferred tax liability - depreciation — ( 38 ) Deferred tax liability - unrealized FX (gain)/loss ( 1 ) — Net deferred tax assets $ — $ — In assessing the realizability of deferred tax assets, management considers whether it is more likely than not that some portion or all of the deferred tax assets will not be realized. Generally, the ultimate realization of deferred tax assets is dependent on the generation of future taxable income during the periods in which those temporary differences become deductible. Based on all relevant factors, a valuation allowance of $ 38.3 million has been established against deferred tax assets as of December 31, 2024, as management determined that it is more likely than not that sufficient taxable income will not be generated to realize those temporary differences. At December 31, 2024, the Company had net operating loss carryforwards of approximately $ 123.9 million and $ 84.3 million available to reduce future taxable income, if any, for federal and state income tax purposes, respectively. The federal net operating loss carryforward began expiring in 2024, and the state net operating loss carryforward will begin expiring in 2028. It is possible that the Company will not generate taxable income in time to use these net operating loss carryforwards before their expiration. In addition, under Section 382 of the Internal Revenue Code of 1986 (the “Code”), as amended, if a corporation undergoes an “ownership change” (as defined in the Code), the corporation’s ability to use its pre-change tax attributes to offset its post-change income may be limited. In general, an “ownership change” occurs if there is a cumulative change in a “loss corporation’s” (as defined in the Code) ownership by 5% shareholders that exceeds 50 percentage points over a rolling three-year period. Management has evaluated the effect of guidance provided by GAAP regarding accounting for uncertainty in income taxes and determined the Company has no uncertain tax positions that could have a significant impact on its consolidated financial statements. The Company’s federal income tax return for 2021 and subsequent years remain open for examination.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	12 Months Ended
	Dec. 31, 2024
Accounting Policies [Abstract]
Principles of Consolidation	Principles of Consolidation The consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All significant intercompany accounts and transactions have been eliminated.
Basis of Presentation and Use of Estimates	Basis of Presentation and Use of Estimates The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the amounts reported in the consolidated financial statements and accompanying notes. On an ongoing basis, the Company evaluates its estimates and judgments, which are based on historical and anticipated results and trends and on various other assumptions that management believes to be reasonable under the circumstances. By their nature, estimates are subject to an inherent degree of uncertainty and, as such, actual results may differ from those estimates.
Cash and Cash Equivalents	Cash and Cash Equivalents Cash and cash equivalents include all highly liquid investments with an original maturity of three months or less from the date of purchase. As of December 31, 2024 , cash equivalents consisted predominantly of U.S. Government debt securities.
Inventory	Inventory Inventory is carried at the lower of cost or net realizable value. The costs of inventory are determined using the standard cost method, which approximates actual cost based on a first-in, first-out method. Items in inventory relate primarily to the Company’s ClearPoint system and related disposables. Software license inventory related to ClearPoint systems undergoing on-site customer evaluation is included in inventory in the accompanying consolidated balance sheets. All other software license inventory is classified as a non-current asset. The Company periodically reviews its inventory for obsolete items and provides a reserve upon identification of potential obsolete items.
Intangible Assets	Intangible Assets The Company is a party to a license agreement that provides rights to the Company for the development and commercialization of products. Under the term of the license agreement, the Company paid an aggregate $ 1.1 million to the licensor upon execution of the license agreement for access to the underlying technology and will make future payments based on the achievement of regulatory and commercialization milestones as defined in the license agreement. In 2022, the Company made a payment of $ 0.6 million to the licensor for the achievement of a regulatory milestone, which acts as a prepayment for future royalties. In conformity with ASC 350, “Intangibles – Goodwill and Other,” the Company amortizes its investment in the upfront license rights described above over an expected useful life of up to five years , or as commercial sales occur for the royalty prepayment. In addition, the Company periodically evaluates the recoverability of its investment in the license rights and records an impairment charge in the event such evaluation indicates that the Company's investment is not likely to be recovered.
Property and Equipment	Property and Equipment Property and equipment are recorded at cost and are depreciated on a straight-line basis over their estimated useful lives, principally three to seven years . Leasehold improvements are depreciated on a straight-line basis over the lesser of their estimated useful lives or the term of the related lease.
Impairment of Long-Lived Assets	Impairment of Long-Lived Assets The Company periodically evaluates the recoverability of its long-lived assets (finite-lived intangible assets and property and equipment). Whenever events or changes in circumstances indicate that the carrying amount of such assets may not be fully recoverable, the expected undiscounted future cash flows are compared to the net book value of the related assets. If the net book value of the related assets were to exceed the undiscounted expected future cash flows of the assets, the carrying amount would be reduced to the present value of the expected future cash flows and an impairment loss would be recognized.
Revenue Recognition	Revenue Recognition The Company’s revenue is comprised primarily of: (1) product revenue resulting from the sale of neurosurgery, navigation, therapy, biologics and drug delivery disposable products, and the sale of ClearPoint capital equipment and software; and (2) service revenue resulting from development services and consultation revenue in connection with customer-sponsored preclinical and clinical trials, as well as revenue resulting from the service, installation, training, and shipping related to ClearPoint capital equipment and software. The Company recognizes revenue when (i) control of the Company’s products is transferred to its customers or (ii) services are provided to customers, each in an amount that reflects the consideration the Company expects to receive from its customers in exchange for those products and services, in a process that involves identifying the contract with a customer, identifying the performance obligations in the contract, determining the transaction price, allocating the transaction price to the distinct performance obligations in the contract, and recognizing revenue when or as the performance obligations have been satisfied. A performance obligation is considered distinct from other obligations in a contract when it provides a benefit to the customer either on its own or together with other resources that are readily available to the customer and is separately identified in the contract. When a contract calls for the satisfaction of multiple performance obligations for a single contract price, the Company typically allocates the contract price among the performance obligations based on the relative stand-alone selling prices for each such performance obligation customarily charged by the Company. The Company considers a performance obligation satisfied once it has transferred control of a good or service to the customer, meaning the customer has the ability to use and obtain the benefit of the good or service. The Company recognizes revenue for satisfied performance obligations only when it determines there are no uncertainties regarding payment terms or transfer of control. Lines of Business; Timing of Revenue Recognition Product Revenue: • Neurosurgery navigation product, biologics and drug delivery systems product, and therapy product sales: Revenue from the sale of neurosurgery navigation products (consisting of disposable products sold commercially and related to cases utilizing the Company's ClearPoint system), biologics and drug delivery systems (consisting primarily of disposable products related to customer-sponsored clinical trials utilizing the ClearPoint system), and therapy products (consisting primarily of disposable laser-related products used in neurosurgical procedures) is generally based on customer purchase orders, the predominance of which require delivery within one week of the order having been placed, and is generally recognized at the point in time of shipping to the customer, which is the point at which legal title, and risks and rewards of ownership, transfer to the customer. For certain customers, legal title and risks and rewards of ownership transfer upon delivery to the customer as stated in their respective contracts, in which case revenue is recognized upon delivery. • Capital equipment and software sales: ◦ Capital equipment and software sales preceded by evaluation periods: The predominance of capital equipment and software sales (consisting of integrated computer hardware and software that are integral components of the Company's ClearPoint system) are preceded by customer evaluation periods. During these evaluation periods, installation of, and training of customer personnel on, the systems have been completed and the systems have been in operation. Accordingly, revenue from capital equipment and software sales following such evaluation periods is recognized at the point in time that the Company is in receipt of an executed purchase agreement or purchase order. ◦ Capital equipment and software sales not preceded by evaluation periods: Revenue from sales of capital equipment and software not having been preceded by an evaluation period is recognized upon delivery to the customer and installation. For capital equipment that does not require installation, revenue is recognized upon shipment, however, for those customers where legal title and risks and rewards of ownership transfer upon delivery, revenue is recognized at such time. For both types of capital equipment and software sales described above, the determination of the point in time at which to recognize revenue represents that point at which the customer has legal title, physical possession, and the risks and rewards of ownership, and the Company has a present right to payment. Service Revenue: • Neurosurgery navigation and therapy services: The Company recognizes revenue for such services over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. • Biologics and drug delivery services and other revenue: ◦ Consultation and Development Services: The Company recognizes consultation and development service revenue over time as the services are delivered to the customer based on the extent of progress towards completion of the performance obligation. The Company may use output methods, such as time elapsed, or input methods, such as labor hours expended or costs incurred, to measure progress depending on which better depicts the transfer of control to the customer. ◦ License fees: The Company grants licenses to customers to develop and commercialize its SmartFlow cannula devices with the customers' proprietary biologics as a combination device. License fees represent the use of functional intellectual property as it exists at the point in time at which the license is granted and does not require any significant development or customization. Accordingly, the Company recognizes license revenue at the point in time in which the license becomes effective and the intellectual property is made available to the customer. ◦ Milestone fees : Event-based payments which are subject to the customer's achievement of specified development or regulatory milestones are included in the transaction price if, in the Company's judgment, it is probable that these milestones will be achieved and a significant future reversal of cumulative revenue under the contract will not occur. The Company re-evaluates the probability of achievement of such milestone at the end of each reporting period and adjusts the transaction price as necessary. • Capital equipment-related services: ◦ Equipment service: Revenue from service of ClearPoint capital equipment and software previously sold to customers is based on agreements with terms ranging from one to three years and is recognized ratably on a monthly basis over the term of the service agreement. A time-elapsed output method is used for service revenue because the Company transfers control evenly by providing a stand-ready service. The Company may also enter into contracts with customers who own ClearPoint capital equipment, which bundle maintenance and support services and access to software and hardware upgrades made commercially available over the term of the contract, for a single contract price, typically paid on an annual basis. The Company allocates the contract price among the performance obligations based on the relative stand-alone prices for each such performance obligation and recognizes the revenue ratably on a monthly basis. A time-elapsed output method is used as the Company is providing a stand-ready service for each of the performance obligations. ◦ Installation, training, and shipping: Consistent with the Company's recognition of revenue for capital equipment and software sales as described above, fees for installation, training, and shipping in connection with sales of capital equipment and software that have been preceded by customer evaluation periods are recognized as revenue at the point in time the Company is in receipt of an executed purchase order for the equipment and software. Installation, training, and shipping fees related to capital equipment and software sales not having been preceded by an evaluation period are recognized as revenue concurrent with the recognition of revenue of the related capital equipment. Payment terms under contracts with customers generally are in a range of 30 - 60 days after the customers’ receipt of the Company’s invoices. The Company's terms and conditions do not provide for a right of return unless for: (a) product defects; or (b) other conditions subject to the Company's approval. See Note 3 for additional information regarding revenue recognition.
Research and Development Costs	Research and Development Costs Costs related to research, design and development of products are charged to research and development expense as incurred.
Income Taxes	Income Taxes Deferred income tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the consolidated financial statement carrying amounts of existing assets and liabilities and their respective income tax bases. Such assets and liabilities are measured using enacted tax rates expected to apply to taxable income or loss in the years in which those temporary differences are expected to be recovered or settled. The effect of a change in tax rates is recognized in the period that includes the enactment date. The Company provides a valuation allowance against net deferred income tax assets unless, based upon available evidence, it is more likely than not the deferred income tax assets will be realized. The Company recognizes interest and penalties related to unrecognized tax benefits as a component of income tax expense. As of December 31, 2024 and 2023 , the Company had no accrued interest or penalties related to uncertain tax positions.
Net Loss Per Share	Net Loss Per Share The Company computes net loss per share using the weighted-average number of common shares outstanding during the period. Basic and diluted net loss per share are the same because the conversion, exercise or issuance of all potential common stock equivalents, which comprise the entire amount of the Company’s outstanding common stock options and unvested RSUs as described in Note 9, would be anti-dilutive, due to the reporting of a net loss for each of the periods in the accompanying consolidated statements of operations. For the years ended December 31, 2024 and 2023, approximately 3 million and 4 million shares, respectively, of common stock equivalents were excluded from the calculation of diluted net loss per common share because their effect was anti-dilutive.
Share-Based Compensation	Share-Based Compensation The Company accounts for compensation for all arrangements under which employees, directors and others receive shares of stock or other equity instruments (such as restricted stock units and options) based on fair value. The fair value of each award is estimated as of the grant date and amortized as compensation expense over the requisite vesting period. Forfeitures are recognized as they occur. In the case of stock options, the fair value is estimated on the grant dates using the Black-Scholes valuation model. This valuation model requires the input of highly subjective assumptions, including the expected stock volatility, estimated award terms and risk-free interest rates for the expected terms. To estimate the expected terms, the Company utilizes the simplified method for “plain vanilla” options discussed in the Staff Accounting Bulletin 107 (“SAB 107”) issued by the SEC. The Company believes that all factors listed within SAB 107 as pre-requisites for utilizing the simplified method apply to the Company and its share-based compensation arrangements. The Company intends to utilize the simplified method for the foreseeable future until more detailed information about exercise behavior becomes available. Expected volatility is based on historical volatility of the Company's common stock. The Company utilizes risk-free interest rates based on U.S. treasury instruments, the terms of which are consistent with the expected terms of the equity awards. The Company has not paid and does not anticipate paying cash dividends on its shares of common stock; therefore, the expected dividend yield is assumed to be zero . The Company did no t grant any stock options in 2024.
Fair Value Determination of Share-Based Transactions	Fair Value Determination of Share-Based Transactions The Company’s common stock is traded on the Nasdaq Capital Market under the symbol “CLPT.” Quoted closing stock prices are used as a key input in determining the fair value for share-based transactions.
Concentration Risks and Other Risks and Uncertainties	Concentration Risks and Other Risks and Uncertainties Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash and cash equivalents and accounts receivable. The Company holds substantially all its cash and cash equivalents on deposit with financial institutions in the U.S. that are insured by the Federal Deposit Insurance Corporation or in U.S. government debt securities. At December 31, 2024, the Company had approximately $ 1.2 million in bank balances that were in excess of the insured limits. At December 31, 2024, there were two customers whose accounts receivable balances aggregated to 24 % of accounts receivable at that date. At December 31, 2023, there were four customers whose accounts receivable balances aggregated to 80 % of accounts receivable at that date. One pharmaceutical customer, a related party that is a stockholder, former noteholder, and whose chief executive officer is a representative on the Company's Board of Directors, for whom the Company provides hardware, software, clinical services, and market development services in support of the customer's clinical trials, and from whom the Company earns a quarterly fee, accounted for 9 % of total revenue for the year ended December 31, 2024 , and of 12 % total revenue for the year ended December 31, 2023 . There were no outstanding receivables from this customer at December 31, 2024 or December 31, 2023. Prior to granting credit, the Company generally performs credit evaluations of its customers’ financial condition. In general, the Company does not require collateral from customers with an extension of credit. The accounts receivable balance is reduced by an allowance for credit losses from the potential inability of the Company's customers to make required payments. The allowance for credit losses at December 31, 2024 and 2023 was $ 1.1 million and $ 1.4 million , respectively. The Company evaluates the historic loss experience on the accounts receivable balance and also considers separately customers with receivable balances that may be negatively impacted by current economic developments and market conditions. The estimate is a result of the Company's ongoing evaluation of collectability, customer creditworthiness, historical levels of credit losses and future expectations. The Company is subject to risks common to emerging companies in the medical device industry, including, but not limited to: new technological innovations; acceptance and competitiveness of its products; dependence on key personnel; dependence on key suppliers; its ability to maintain its third-party collaboration, license and joint development partners; changes in general economic conditions and interest rates; its ability to obtain additional funding to support its business; regulatory uncertainty; protection of proprietary technology; compliance with changing government regulations; uncertainty of widespread market acceptance of products; access to credit for capital purchases by customers; and product liability claims. Certain components used in manufacturing have relatively few alternative sources of supply and establishing additional or replacement suppliers for such components cannot be accomplished quickly. The inability of any of these suppliers to fulfill the Company’s supply requirements may negatively impact future operating results.
Recent Accounting Standards Adopted and Recent Accounting Standards Not Yet Adopted	Recent Accounting Standards Adopted In November 2023, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2023-07, “Segment Reporting (Topic 280): Improvements to Reportable Segment Disclosures.” The amendments improve reportable segment disclosure requirements, primarily through enhanced disclosures about significant segment expenses. In addition, the amendments enhance interim disclosure requirements, clarify circumstances in which an entity can disclose multiple segment measures of profit or loss, provide new segment disclosure requirements for entities with a single reportable segment, and contain other disclosure requirements. The Company adopted the ASU on its annual reporting for the year ended December 31, 2024. See Note 10 in the accompanying notes to the consolidated financial statements for further detail. In June 2016, the FASB issued ASU 2016-13, “Financial Instruments - Credit Losses (Topic 326),” which replaces the previous incurred loss impairment methodology for most financial assets with the current expected credit loss, or CECL, methodology. The new guidance requires entities to use a forward-looking approach based on expected losses rather than incurred losses to estimate credit losses on certain types of financial instruments, including trade receivables. The Company adopted the new standard effective January 1, 2023 , which did not have a material impact to the consolidated financial statements. Recent Accounting Standards Not Yet Adopted In December 2023, the FASB issued ASU 2023-09, “Improvements to Income Tax Disclosures,” which requires that an entity, on an annual basis, disclose additional income tax information, primarily related to the rate reconciliation and income taxes paid. The provisions of the ASU are intended to enhance the transparency and decision usefulness of income tax disclosures. The guidance will be applied on a prospective basis with the option to apply the standard retrospectively and is effective for calendar year-end public business entities in the 2025 annual period and in 2026 for interim periods with early adoption permitted. The Company is currently evaluating the impact of this ASU on its consolidated financial statements. In November 2024, the FASB issued ASU 2024-03, “Income Statement-Reporting Comprehensive Income-Expense Disaggregation Disclosures (Subtopic 220-40): Disaggregation of Income Statement Expenses,” which requires disclosure about the types of costs and expenses included in certain expense captions presented on the income statement. The new disclosure requirements are effective for the Company's annual periods beginning after December 15, 2026, and interim periods beginning after December 15, 2027, with early adoption permitted. The Company is currently evaluating the impact of this pronouncement on its related disclosures.

Revenue Recognition (Tables)

Revenue Recognition (Tables)	12 Months Ended
	Dec. 31, 2024
Revenue from Contract with Customer [Abstract]
Schedule of Revenue by Service Line	Revenue by Service Line Years Ended December 31, (in thousands) 2024 2023 Biologics and drug delivery Disposable products $ 5,606 $ 2,154 Services and license fees 11,704 11,448 Subtotal – Biologics and drug delivery revenue 17,310 13,602 Neurosurgery navigation and therapy Disposable products 10,285 7,589 Services — 931 Subtotal – Neurosurgery navigation and therapy revenue 10,285 8,520 Capital equipment and software Systems and software products 2,735 860 Services 1,060 973 Subtotal – Capital equipment and software revenue 3,795 1,833 Total revenue $ 31,390 $ 23,955
Schedule of Other Current Assets	(in thousands) December 31, 2024 December 31, 2023 December 31, 2022 Accounts receivable, net $ 4,713 $ 3,211 $ 2,665 Other contract assets Unbilled receivables $ 642 $ 733 $ 43 Deferred contract costs $ — $ — $ 327
Schedule of Revenue Recognized by Contract Liability	(in thousands) December 31, 2024 December 31, 2023 December 31, 2022 Deferred revenues $ 2,557 $ 3,154 $ 1,457 Refund liability $ — $ — $ 500

Inventory (Tables)

Inventory (Tables)	12 Months Ended
	Dec. 31, 2024
Inventory Disclosure [Abstract]
Schedule of Inventory	Inventory consists of the following as of December 31: (in thousands) 2024 2023 Raw materials and work in process $ 5,503 $ 6,466 Software licenses 265 211 Finished goods 1,095 1,234 Inventory included in current assets 6,863 7,911 Software licenses – non-current 103 386 $ 6,966 $ 8,297

Property and Equipment (Tables)

Property and Equipment (Tables)	12 Months Ended
	Dec. 31, 2024
Property, Plant and Equipment [Abstract]
Schedule of Property, Plant and Equipment	Property and equipment consist of the following as of December 31: (in thousands) 2024 2023 Equipment $ 1,558 $ 1,108 Leasehold improvements 485 485 Loaned systems 1,305 741 3,348 2,334 Less accumulated depreciation and amortization ( 1,343 ) ( 945 ) Total property and equipment, net $ 2,005 $ 1,389

Commitments and Contingencies (

Commitments and Contingencies (Tables)	12 Months Ended
	Dec. 31, 2024
Leases [Abstract]
Schedule of Future Minimum Lease Payments	As of December 31, 2024, future minimum lease payments are as follows: Years ending December 31, (in thousands) 2025 $ 954 2026 985 2027 502 2028 520 2029 538 Thereafter 1,981 Total minimum payments 5,480 Less: Discount to present value of lease payments ( 1,912 ) Discounted present value of lease payments $ 3,568

Stockholders' Equity (Tables)

Stockholders' Equity (Tables)	12 Months Ended
	Dec. 31, 2024
Equity [Abstract]
Summary of Share-Based Compensation Expense	The following table sets forth share-based compensation expense included in the consolidated statements of operations: Years Ended December 31, (in thousands) 2024 2023 Cost of revenue $ 112 $ 101 Research and development 1,641 1,352 Sales and marketing 1,881 1,717 General and administrative 3,273 2,909 Share-based compensation expense $ 6,907 $ 6,079 Share-based compensation expense by type of share-based award: Years Ended December 31, (in thousands) 2024 2023 Stock options $ 653 $ 956 RSAs and RSUs 6,066 4,903 ESPP 188 220 $ 6,907 $ 6,079 Total unrecognized compensation expense by type of award and the weighted-average remaining requisite service period over which such expense is expected to be recognized (in thousands, unless otherwise noted): December 31, 2024 Unrecognized Remaining Stock options $ 300 0.92 RSAs and RSUs $ 7,815 1.68
Summary of Stock Option Activity	Stock option activity under all of the Company’s Plans as of and for the year ended December 31, 2024 is summarized below: Stock Weighted- Weighted- Intrinsic (1) Outstanding at December 31, 2023 1,478,157 $ 8.40 Exercised ( 19,090 ) $ 5.21 Forfeited or expired ( 82,671 ) $ 41.12 Outstanding at December 31, 2024 1,376,396 $ 6.48 4.70 $ 13,217 Exercisable at December 31, 2024 1,252,409 $ 6.22 4.38 $ 12,444 Vested and expected to vest at December 31, 2024 1,376,396 $ 6.48 4.70 $ 13,217 (1) Intrinsic value is calculated as the estimated fair value of the Company’s stock at December 31, 2024 less the option exercise price of in-the-money options.
Summary of Non-vested Stock Options	A summary of the status of the Company’s non-vested stock options for the year ended December 31, 2024 is presented below: Non-vested Stock Weighted- Nonvested, December 31, 2023 226,215 $ 7.37 Vested ( 95,544 ) $ 8.09 Forfeited ( 6,684 ) $ 7.05 Nonvested, December 31, 2024 123,987 $ 6.83
Summary of Fair Value Assumptions	The fair value of each stock option is estimated on the date of grant using the Black-Scholes valuation model utilizing the following weighted average assumptions for options granted during the years ended December 31, 2024 and 2023: Years Ended December 31, 2024 2023 Risk-free interest rate — 4.17 % Expected life (in years) — 6.10 Estimated volatility — 81.21 % Expected dividends — None The fair value of the purchase options under the ESPP are estimated at the beginning of the purchase period using the Black-Scholes valuation model utilizing the following assumptions: 2024 2023 Risk-free interest rate 5.24 % - 5.37 % 4.77 % - 5.53 % Expected life (in years) 0.5 0.5 Estimated volatility 64.5 % - 67.33 % 61.41 % - 62.37 % Expected dividends None None
Schedule of Restricted Stock Activity	RSA activity as of and for the year ended December 31, 2024 is summarized below ( no RSAs were granted in 2024): Restricted Stock Weighted- Outstanding at December 31, 2023 376,914 $ 12.02 Vested ( 212,583 ) $ 12.67 Forfeited or expired ( 10,121 ) $ 11.97 Outstanding at December 31, 2024 154,210 $ 11.12 RSU activity as of and for the year ended December 31, 2024 is summarized below: Restricted Stock Weighted- Outstanding at December 31, 2023 768,139 $ 8.15 Granted 1,202,228 $ 6.18 Vested ( 270,673 ) $ 8.01 Forfeited or expired ( 41,934 ) $ 7.65 Outstanding at December 31, 2024 1,657,760 $ 6.76

Income Taxes (Tables)

Income Taxes (Tables)	12 Months Ended
	Dec. 31, 2024
Income Tax Disclosure [Abstract]
Schedule of Components of Income Tax Expense (Benefit)	Years Ended December 31, (in thousands) 2024 2023 Income tax benefit at federal statutory rate $ ( 3,992 ) $ ( 4,584 ) Adjustments for tax effects of: State income tax, net of federal benefit ( 650 ) ( 1,191 ) Permanent adjustments 305 49 Benefit state rate change 136 ( 23 ) Other 144 152 Share-based compensation 1,336 520 Net operating loss write-off 216 ( 574 ) Change in valuation allowance 2,517 5,659 Income tax expense $ 12 $ 8
Schedule of Deferred Tax Assets and Liabilities	The tax effect of temporary differences and carryforwards that give rise to significant portions of the deferred income tax assets are as follows: Years Ended December 31, (in thousands) 2024 2023 Deferred income tax assets: Net operating loss carryforwards $ 31,776 $ 30,145 Share-based compensation 1,390 2,193 Accrued expenses 295 319 174 Capitalization 4,606 3,026 Other 267 170 38,334 35,853 Less valuation allowance ( 38,333 ) ( 35,815 ) Total deferred income tax assets 1 38 Deferred tax liability - depreciation — ( 38 ) Deferred tax liability - unrealized FX (gain)/loss ( 1 ) — Net deferred tax assets $ — $ —

Description of the Business a_2

Description of the Business and Financial Condition - Additional Information (Details) $ in Thousands	1 Months Ended				12 Months Ended
	Nov. 30, 2024 USD ($)	Aug. 31, 2024 USD ($) Investor	Mar. 31, 2024 USD ($) shares	May 31, 2021 USD ($)	Dec. 31, 2024 USD ($) Customer shares	Dec. 31, 2023 USD ($) shares	Jan. 31, 2020 Investor
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Number of customers | Customer					60
Cumulative deficit					$ 191,370	$ 172,456
Net cash used in operations					8,950	13,720
Net proceeds from offering					$ 16,149	$ 0
Common stock, shares issued (in shares) | shares					27,617,415	24,652,729
Public Offering
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Public offering (in shares) | shares			2,653,848
Net proceeds from offering			$ 16,200
At-The-Market Equity Offering
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Sale of stock maximum proceeds on potential common stock offering	$ 50,000
Common stock, shares issued (in shares) | shares					0
Security Purchase Agreement | Convertible Debt
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Debt instrument, number of investors | Investor		2
Gross proceeds from issued secured convertible notes		$ 25,000
Debt instrument, conversion amount		15,000
Security Purchase Agreement | Convertible Debt | First Closing Notes
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Repayments of debt		$ 10,000
Debt instrument, number of investors | Investor							2
Debt instrument, conversion amount				$ 7,500

Summary of Significant Accoun_3

Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Product Information [Line Items]
Stock option granted	0
Unrecognized tax benefits, accrued interest or penalties	$ 0	$ 0
Antidilutive securities excluded from computation of earnings per share (in shares)	3,000,000	4,000,000
Expected dividends	0%
Cash, uninsured amount	$ 1,200,000
Allowance for doubtful accounts	$ 1,100,000	$ 1,400,000
ASU 2016-13
Product Information [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Change in Accounting Principle, Accounting Standards Update, Adoption Date	Jan. 01, 2023
Change in Accounting Principle, Accounting Standards Update, Immaterial Effect [true false]	false
ASU 2023-07
Product Information [Line Items]
Change in Accounting Principle, Accounting Standards Update, Adopted [true false]	true
Related Party
Product Information [Line Items]
Outstanding receivable	$ 0	$ 0
Accounts Receivable | Customer Concentration Risk | Two Customers
Product Information [Line Items]
Concentration risk, percentage	24%
Accounts Receivable | Customer Concentration Risk | Four Customers
Product Information [Line Items]
Concentration risk, percentage		80%
Revenue Benchmark | Customer Concentration Risk | Related Party
Product Information [Line Items]
Concentration risk, percentage	9%	12%
Minimum
Product Information [Line Items]
Estimated useful life	3 years
Term of service agreements	1 year
Payment terms	30 days
Maximum
Product Information [Line Items]
Intangible asset, useful life (up to)	5 years
Estimated useful life	7 years
Term of service agreements	3 years
Payment terms	60 days
License Agreement Terms
Product Information [Line Items]
Payments to acquire productive assets	$ 1,100,000
Prepayment for future royalties			$ 600,000

Revenue Recognition - Schedule

Revenue Recognition - Schedule of Revenue by Service Line (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Disaggregation of Revenue [Line Items]
Total revenue	$ 31,390	$ 23,955
Biologics and drug delivery
Disaggregation of Revenue [Line Items]
Total revenue	17,310	13,602
Biologics and Drug Delivery - Disposable Products
Disaggregation of Revenue [Line Items]
Total revenue	5,606	2,154
Biologics and Drug Delivery - Services and License Fees
Disaggregation of Revenue [Line Items]
Total revenue	11,704	11,448
Neurosurgery navigation and therapy
Disaggregation of Revenue [Line Items]
Total revenue	10,285	8,520
Neurosurgery Navigation and Therapy - Disposable Products
Disaggregation of Revenue [Line Items]
Total revenue	10,285	7,589
Neurosurgery Navigation and Therapy - Services
Disaggregation of Revenue [Line Items]
Total revenue	0	931
Capital equipment and software
Disaggregation of Revenue [Line Items]
Total revenue	3,795	1,833
Capital Equipment and Software - Systems and Software Products
Disaggregation of Revenue [Line Items]
Total revenue	2,735	860
Capital Equipment and Software - Services
Disaggregation of Revenue [Line Items]
Total revenue	$ 1,060	$ 973

Revenue Recognition - Additiona

Revenue Recognition - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Disaggregation of Revenue [Line Items]
Refund liability	$ 0	$ 0	$ 500
Total revenue	$ 31,390	23,955
Minimum
Disaggregation of Revenue [Line Items]
Contract liabilities, service agreements, terms	1 year
Maximum
Disaggregation of Revenue [Line Items]
Contract liabilities, service agreements, terms	3 years
Capital Equipment Related Service Revenue
Disaggregation of Revenue [Line Items]
Total revenue	$ 2,300	$ 1,100
Capital Equipment and Software-Related Service
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, amount	$ 2,500
Capital Equipment and Software-Related Service | Revenue, Remaining Performance Obligation, Expected Timing of Satisfaction, Start Date [Axis]: 2025-01-01
Disaggregation of Revenue [Line Items]
Revenue, remaining performance obligation, percentage	83%
Revenue, remaining performance obligation, period	12 months

Revenue Recognition - Schedul_2

Revenue Recognition - Schedule of Other Current Assets (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Accounts receivable, net	$ 4,713	$ 3,211	$ 2,665
Other contract assets
Unbilled receivables	642	733	43
Deferred contract costs	$ 0	$ 0	$ 327

Revenue Recognition - Schedul_3

Revenue Recognition - Schedule of Revenue Recognized by Contract Liability (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023	Dec. 31, 2022
Revenue from Contract with Customer [Abstract]
Deferred revenues	$ 2,557	$ 3,154	$ 1,457
Refund Liability	$ 0	$ 0	$ 500

Fair Value Measurement - Additi

Fair Value Measurement - Additional Information (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Fair Value Disclosures [Abstract]
Cash and cash equivalents	$ 20,104	$ 23,140

Inventory - Schedule of Invento

Inventory - Schedule of Inventory (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Raw materials and work in process	$ 5,503	$ 6,466
Software licenses	265	211
Finished goods	1,095	1,234
Inventory included in current assets	6,863	7,911
Software licenses – non-current	103	386
Total	$ 6,966	$ 8,297

Inventory - Additional Informat

Inventory - Additional Information (Details) - USD ($) $ in Millions	Dec. 31, 2024	Dec. 31, 2023
Inventory Disclosure [Abstract]
Inventory valuation reserves	$ 2.3	$ 2

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Line Items]
Property and equipment	$ 3,348	$ 2,334
Less accumulated depreciation and amortization	(1,343)	(945)
Total property and equipment, net	2,005	1,389
Equipment
Property, Plant and Equipment [Line Items]
Property and equipment	1,558	1,108
Leasehold improvements
Property, Plant and Equipment [Line Items]
Property and equipment	485	485
Loaned systems
Property, Plant and Equipment [Line Items]
Property and equipment	$ 1,305	$ 741

Property and Equipment - Additi

Property and Equipment - Additional Information (Details) - USD ($) $ in Millions	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 0.2	$ 0.2

Notes Payable - Additional Info

Notes Payable - Additional Information (Details) $ / shares in Units, $ in Thousands		1 Months Ended
	Aug. 23, 2024 USD ($)	Aug. 31, 2024 USD ($) Investor	Nov. 30, 2021 USD ($) shares	May 31, 2021 USD ($) shares	Jan. 31, 2020 USD ($) Investor $ / shares	Dec. 31, 2024 USD ($)	Dec. 31, 2023 USD ($)	Dec. 31, 2020 USD ($)
Debt Instrument [Line Items]
Secured convertible notes						$ 0	$ 9,949
First Closing Notes | Fair Value, Inputs, Level 3
Debt Instrument [Line Items]
Fair value disclosure							$ 12,500
Security Purchase Agreement | Convertible Debt
Debt Instrument [Line Items]
Number of investors | Investor		2
Debt instrument, conversion amount		$ 15,000
Security Purchase Agreement | Convertible Debt | First Closing Notes
Debt Instrument [Line Items]
Number of investors | Investor					2
Debt instrument, face amount					$ 17,500
Debt instrument, variable interest rate					2%
Debt instrument, basis spread on variable rate					2%
Debt instrument, conversion price (in dollars per share) | $ / shares					$ 6
Debt instrument, conversion amount				$ 7,500
Accrued interest included in the conversion of debt				$ 40
Debt conversion, shares issued (in shares) | shares				1,256,143
Principal repayment	$ 10,000
Accrued interest	$ 100
Security Purchase Agreement | Convertible Debt | Second Closing Note
Debt Instrument [Line Items]
Debt instrument, face amount			$ 7,500					$ 7,500
Security Purchase Agreement Amended | Convertible Debt | Second Closing Note
Debt Instrument [Line Items]
Debt conversion, shares issued (in shares) | shares			773,446
Amount of accrued and paid-in-kind interest included in converted debt			$ 300

Commitments and Contingencies -

Commitments and Contingencies - Additional Information (Details) $ in Millions	12 Months Ended
	Dec. 31, 2024 USD ($) OptionToExtend	Dec. 31, 2023 USD ($)
Lessee, Lease, Description [Line Items]
Operating lease, weighted average remaining lease term	6 years 9 months 21 days	7 years 4 months 17 days
Operating lease, weighted average discount rate, percent	12%	11.80%
Lease, cost	$ 0.9	$ 0.6
Purchase orders and contractual obligations	$ 1.2
Contractual obligation in the ordinary course of business, term	1 year
License and collaboration agreement, minimum purchase commitment term	7 years
Remaining minimum purchase commitment	5 years
Loss contingency plaintiff amount	$ 13.6
Office Lease - Solana Beach, California
Lessee, Lease, Description [Line Items]
Lessee, operating lease, term of contract (in years)	5 years
Office Lease - Irvine, California
Lessee, Lease, Description [Line Items]
Renew the lease for two additional periods	5 years
Leased Office and Manufacturing Facility
Lessee, Lease, Description [Line Items]
Number of options to extend | OptionToExtend	2
Minimum purchase commitment	$ 4.2
Leased Office and Manufacturing Facility | Minimum
Lessee, Lease, Description [Line Items]
Renew the lease for two additional periods	36 months
Leased Office and Manufacturing Facility | Maximum
Lessee, Lease, Description [Line Items]
Renew the lease for two additional periods	60 months

Commitments and Contingencies_2

Commitments and Contingencies - Schedule of Future Minimum Lease Payments (Details) $ in Thousands	Dec. 31, 2024 USD ($)
Lessee, Operating Lease, Liability, Payment, Due [Abstract]
2025	$ 954
2026	538
2027	985
2028	502
2029	520
Thereafter	1,981
Total minimum payments	5,480
Less: Discount to present value of lease payments	(1,912)
Discounted present value of lease payments	$ 3,568

Stockholders' Equity - Addition

Stockholders' Equity - Additional Information (Details) - USD ($)		1 Months Ended			12 Months Ended
	Jun. 03, 2021	Nov. 30, 2024	Mar. 31, 2024	Jul. 31, 2021	Dec. 31, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares issued (in shares)					27,617,415	24,652,729
Net proceeds from offering					$ 16,149,000	$ 0
Share-based payment award, options, outstanding, number (in shares)					1,376,396	1,478,157
Purchase plan, shares purchased (in shares)					97,093
Public Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Public offering (in shares)			2,653,848
Common stock initially offered at public offering (in shares)			2,307,694
Sale of stock, price per share (in usd per share)			$ 6.5
Shares sold pursuant to exercise of underwriters option (in shares)			346,154
Net proceeds from offering			$ 16,200,000
At-The-Market Equity Offering
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, shares issued (in shares)					0
Sale of stock maximum proceeds on potential common stock offering		$ 50,000,000
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Percent of fair market value of common stock on the date of grant threshold					100%
Expiration period					10 years
Non-vested Stock Options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in usd per share)					$ 0	$ 5.85
Intrinsic value of stock options exercised					$ 100,000	$ 100,000
Grant-date fair value of stock options vested					$ 800,000	900,000
RSAs and RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)					0
Fair value of RSAs vested					$ 4,900,000	$ 3,100,000
RSAs and RSUs | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vest in annual installments					2 years
RSAs and RSUs | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vest in annual installments					3 years
2013 Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Common stock, capital shares reserved for future issuance (in shares)					6,106,250
Share-based payment award, options, outstanding, number (in shares)					2,749,616
Shares available for grant (in shares)					1,230,813
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Shares available for grant (in shares)	400,000				138,998
Granted (in usd per share)					$ 2.1	$ 2.57
Purchase plan, purchase price of common stock, percent of fair value	85%
Purchase plan, maximum employee subscription rate	15%
Purchase plan, maximum purchase value during offering period, per employee	$ 25,000
Purchase plan, maximum number of shares per employee (in shares)	3,500
Purchase period	6 months			6 months
Purchase plan, per share weighted average price of shares purchased (in usd per share)					$ 4.56
Related Party | RSAs and RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vest in annual installments					1 year

Stockholders' Equity - Summary

Stockholders' Equity - Summary of Share Based Compensation Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 6,907	$ 6,079
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	653	956
RSAs and RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	6,066	4,903
ESPP
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	188	220
Cost of revenue
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	112	101
Research and development
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	1,641	1,352
Sales and marketing
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	1,881	1,717
General and administrative
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 3,273	$ 2,909

Stockholders' Equity - Summar_2

Stockholders' Equity - Summary of Unrecognized Compensation Expense and Weighted-Average Requisite Period (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Remaining Weighted-Average Recognition Period (in years)	4 years 8 months 12 days
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 300
Remaining Weighted-Average Recognition Period (in years)	11 months 1 day
RSAs and RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized Expense	$ 7,815
Remaining Weighted-Average Recognition Period (in years)	1 year 8 months 4 days

Stockholders' Equity - Schedule

Stockholders' Equity - Schedule of Stock Option Activity (Details) $ / shares in Units, $ in Thousands	12 Months Ended
	Dec. 31, 2024 USD ($) $ / shares shares
Stock Options
Outstanding at beginning (in shares)	1,478,157
Granted (in shares)	0
Exercised (in shares)	(19,090)
Forfeited or expired (in shares)	(82,671)
Outstanding at ending (in shares)	1,376,396
Exercisable at ending (in shares)	1,252,409
Vested and expected to vest at ending (in shares)	1,376,396
Weighted-average Exercise price per share
Outstanding at beginning (in usd per share) | $ / shares	$ 8.4
Exercised (in usd per share) | $ / shares	5.21
Forfeited or expired (in usd per share) | $ / shares	41.12
Outstanding at ending (in usd per share) | $ / shares	6.48
Exercisable at ending (in usd per share) | $ / shares	6.22
Vested and expected to vest (in usd per share) | $ / shares	$ 6.48
Weighted-average Remaining Contractual Life (in years)
Outstanding	4 years 8 months 12 days
Exercisable	4 years 4 months 17 days
Vested and expected to vest	4 years 8 months 12 days
Intrinsic value, outstanding | $	$ 13,217
Intrinsic value, exercisable | $	12,444
Intrinsic value, vested and expected to vest | $	$ 13,217

Stockholders' Equity - Schedu_2

Stockholders' Equity - Schedule of Non-vested Stock Options (Details)	12 Months Ended
	Dec. 31, 2024 $ / shares shares
Non-vested Stock Options
Balance at beginning (in shares)	226,215
Granted (in shares)	0
Vested (in shares)	(95,544)
Forfeited (in shares)	(6,684)
Balance at ending (in shares)	123,987
Weighted - Average Grant Date Fair Value
Balance at beginning (in usd per share) | $ / shares	$ 7.37
Vested (in usd per share) | $ / shares	8.09
Forfeited (in usd per share) | $ / shares	7.05
Balance at ending (in usd per share) | $ / shares	$ 6.83

Stockholders' Equity - Summar_3

Stockholders' Equity - Summary of Weighted Average Assumptions (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Equity [Abstract]
Risk-free interest rate	0%	4.17%
Expected life (in years)	0 years	6 years 1 month 6 days
Estimated volatility	0%	81.21%
Expected dividends	0%

Stockholders' Equity - Schedu_3

Stockholders' Equity - Schedule of Restricted Stock Activity (Details)	12 Months Ended
	Dec. 31, 2024 $ / shares shares
RSAs
Restricted Stock Awards
Outstanding at beginning (in shares)	376,914
Granted (in shares)	0
Vested (in shares)	(212,583)
Forfeited or expired (in shares)	(10,121)
Outstanding at ending (in shares)	154,210
Weighted - Average Grant Date Fair Value
Outstanding at beginning (in usd per share) | $ / shares	$ 12.02
Vested (in usd per share) | $ / shares	12.67
Forfeited or expired (in usd per share) | $ / shares	11.97
Outstanding at ending (in usd per share) | $ / shares	$ 11.12
RSUs
Restricted Stock Awards
Outstanding at beginning (in shares)	768,139
Granted (in shares)	1,202,228
Vested (in shares)	(270,673)
Forfeited or expired (in shares)	(41,934)
Outstanding at ending (in shares)	1,657,760
Weighted - Average Grant Date Fair Value
Outstanding at beginning (in usd per share) | $ / shares	$ 8.15
Granted (in usd per share) | $ / shares	6.18
Vested (in usd per share) | $ / shares	8.01
Forfeited or expired (in usd per share) | $ / shares	7.65
Outstanding at ending (in usd per share) | $ / shares	$ 6.76

Stockholders' Equity - Summar_4

Stockholders' Equity - Summary of Fair Value Assumptions (Details)	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected life (in years)	0 years	6 years 1 month 6 days
Expected dividends	0%
Employee Stock Purchase Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate, minimum	5.24%	4.77%
Risk-free interest rate, maximum	5.37%	5.53%
Expected life (in years)	6 months	6 months
Estimated volatility, minimum	64.50%	61.41%
Estimated volatility, maximum	67.33%	62.37%

Segment Disclosures - Additiona

Segment Disclosures - Additional Information (Details)	12 Months Ended
	Dec. 31, 2024 Segment
Segment Reporting [Abstract]
Segment Reporting, CODM, Individual Title and Position or Group Name [Extensible Enumeration]	srt:ChiefExecutiveOfficerMember
Number of reportable segments	1
Segment reporting, codm, profit (loss) measure, how used, description	The CODM regularly reviews disaggregated revenue data by product line as disclosed in Note 3; however, consolidated net income is utilized as the measure of profit and loss to assess performance of the business and determination on how to allocate resources.
Segment reporting, expense information used by codm, description	Significant expenses within net income include cost of revenue, research and development, sales and marketing, and general and administrative expenses, which are each separately presented on the Company's Consolidated Statements of Operations.
Segment reporting, no asset information [true false]	true

Income Taxes - Additional Infor

Income Taxes - Additional Information (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Operating Loss Carryforwards [Line Items]
Income tax expense	$ 12	$ 8
Percentage of valuation allowance	100%
Valuation allowance against deferred tax	$ 38,333	$ 35,815
Domestic Tax Authority
Operating Loss Carryforwards [Line Items]
Operating loss	123,900
State and Local Jurisdiction
Operating Loss Carryforwards [Line Items]
Operating loss	$ 84,300

Income Taxes - Schedule of Comp

Income Taxes - Schedule of Components of Income Tax Expense (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2024	Dec. 31, 2023
Income Tax Disclosure [Abstract]
Income tax benefit at federal statutory rate	$ (3,992)	$ (4,584)
State income tax, net of federal benefit	(650)	(1,191)
Permanent adjustments	305	49
Benefit state rate change	136	(23)
Other	144	152
Share-based compensation	1,336	520
Net operating loss write-off	216	(574)
Change in valuation allowance	2,517	5,659
Income tax expense	$ 12	$ 8

Income Taxes - Schedule of Defe

Income Taxes - Schedule of Deferred Income Tax Assets and Liabilities (Details) - USD ($) $ in Thousands	Dec. 31, 2024	Dec. 31, 2023
Deferred income tax assets:
Net operating loss carryforwards	$ 31,776	$ 30,145
Share-based compensation	1,390	2,193
Accrued expenses	295	319
174 Capitalization	4,606	3,026
Other	267	170
Deferred income tax assets (liabilities), gross	38,334	35,853
Less valuation allowance	(38,333)	(35,815)
Total deferred income tax assets	1	38
Deferred tax liability - depreciation	0	(38)
Deferred tax liability - unrealized FX (gain)/loss	(1)	0
Net deferred tax assets	$ 0	$ 0